Tauopathies: new perspectives and challenges

Yi Zhang, Kai‑Min Wu, Liu Yang, Qiang Dong and Jin‑Tai Yu* © The Author(s) 2022. Open Access

Abstract
Background: Tauopathies are a class of neurodegenerative disorders characterized by neuronal and/or glial tau-positive inclusions.
Main body: Clinically, tauopathies can present with a range of phenotypes that include cognitive/behavioral disorders, movement disorders, language disorders and non-specific amnestic symptoms in advanced age. Pathologically, tauopathies can be classified based on the predominant tau isoforms that are present in the inclusion bodies (i.e., 3R, 4R or equal 3R:4R ratio). Imaging, cerebrospinal fluid (CSF) and blood-based tau biomarkers have the potential to be used as a routine diagnostic strategy and in the evaluation of patients with tauopathies. As tauopathies are strongly linked neuropathologically and genetically to tau protein abnormalities, there is a growing interest in pursuing of tau-directed therapeutics for the disorders. Here we synthesize emerging lessons on tauopathies from clinical, pathological, genetic, and experimental studies toward a unified concept of these disorders that may accelerate the therapeutics.
Conclusions: Since tauopathies are still untreatable diseases, efforts have been made to depict clinical and pathological characteristics, identify biomarkers, elucidate underlying pathogenesis to achieve early diagnosis and develop disease-modifying therapies.

Keywords: Tauopathies, Neurodegeneration, Biomarkers, Therapeutics, Genetics

Background
“Tauopathies” was coined as an umbrella word depicting some neurodegenerative disorders [1], which are characterized by tau deposits in the brain (mainly in neurons, also in glial cells and extracellular space), with symptoms of dementia and parkinsonism. Currently, more than 26 different tauopathies have been identified [2]. Depending on the major tau isoforms appearing in aggregates, tauopathies are usually classified into 3R tauopathies (mainly having 3R tau), 4R tauopathies (mainly having 4R tau) and 3R/4R tauopathies (with approximately an equal ratio of 3R tau and 4R tau). Besides, in primary tauopathies, tau is the major and prominent component of the pathology, such as PiD (Pick’s disease), PSP (Progressive supranuclear palsy), CBD (corticobasal degeneration) and AGD (Argyrophilic grain disease). While in secondary tauopathies, tau aggregation is regarded as a response to other pathological proteins or events [2], like amyloid beta (Aβ) in AD (Alzheimer’s disease) and repetitive brain injury in CTE (chronic traumatic encephalopathy).

Tauopathies have varied symptoms and complicated manifestations and pathology overlap. Moreover, the mechanisms underlying neurodegeneration of tauopathies are intricate, among which pathological tau forms, tau aggregation and propagation may play important roles. Though risk for tauopathies is partially attributed to genetics, study of related genetic variants helps to understand the mechanisms of disease. Nowadays,
biomarkers and preclinical studies greatly subserve the diagnosis and treatment of tauopathies. In this review, we summarize recent reports about epidemiology, clinical phenotypes, pathology, genetics and the development and challenges in tau related biomarkers and therapies.

Main text

Tau structure and function

Tau is encoded by the microtubule associated protein tau (MAPT) gene, which is located on chromosome 17q21.3, containing 16 exons. In its precursor messenger RNA (pre-mRNA), alternative splicing of exon 2 (E2), E3 and E10 generates six tau isoforms, and the length range of tau protein is between 352 and 441 amino acids [1] (Fig. 1). Depending on the existence of three or four repeats of MTBDs (microtubule binding domains), tau can be classified into 3R tau (exon 10 exclusion) and 4R tau (exon 10 inclusion) [1, 3]. No isoform contains an isolated E3 without E2. The levels of the 3R and 4R isoforms are approximately equal in the adult human brain [4]. Another less discussed tau isoform is Big tau, which is also generated from alternative splicing of pre-mRNA from the MAPT gene. It has an extra E4a, leading to its higher molecular weight ~ 110 kDa. Due to its large size and few phosphorylated sites, Big tau was hypothesized to have a lower propensity to form pathological misfolding. This theory is in line with spared PNS (peripheral nervous system) in tauopathies, where Big tau is mainly expressed [5].

Tau mainly exists in the axons of neurons under physiological conditions [1]. The MTBDs bind to tubulins, promoting microtubule assembly and stability. In addition, tau knock-out mice developed glucose intolerance, pancreatic disorders, anxiety, and impairment of contextual and cued fear memory, implying a wide range of undiscovered functions of tau [8]. Tau also plays a role in protecting genomic architecture, regulating myelination and synaptic plasticity, iron homeostasis, and neurogenesis [9, 10]. Further scrutiny might influence anti-tau therapies as the physiological functions of tau are unintentionally disturbed by treatment.

Regulation of affinity between tau and microtubules mainly depends on phosphorylation of tau, which mostly happens in proline-rich region and C-terminus [11]. However, hyperphosphorylation at some sites will reduce binding affinity, resulting in instability of microtubules, also affecting axonal transport and neurotransmission [11]. Besides, other alterations of tau such as overexpression, mutations, other aberrant posttranslational modifications in addition to phosphorylation (acetylation, truncation, O-GlcNAcylation, etc.), abnormal ratio between tau isoforms and mis-localization could lead to pathological changes observed in tauopathies [10].

The role of tau in neurodegeneration is still not elucidated. Mechanisms have been commonly summarized as loss of function, gain of function and mislocalization due to tau abnormality [10]. A recent study characterized tau interactomes in human induced pluripotent stem cell (iPSC)-derived neurons. They revealed the direct interactions between pathological tau and proteins, including SNARE complex, RNA-binding proteins, and mitochondrial proteins, which influenced tau release, protein synthesis and energy supply respectively. It helped to discover tau mediated pathogenesis and potential therapeutic strategies [12].

Epidemiology of tauopathies

According to WHO, more than 55.2 million people worldwide currently suffer from dementia, with approximately 7 million new cases per year, and the data will increase to 139 million in 2050 [13]. Aging is still the greatest risk factor of all. A cross-sectional study recruiting 46,011 adults over 60 in China suggested a significantly higher prevalence of dementia in population with older age (OR: 2.69–6.60), female gender (OR: 1.43) and family history (OR: 7.20) [14]. Other modifiable risk factors include education, overall health [15], lifestyle, rural residence and environmental factors [16] like PM 2.5 [17] and transportation noise [18].

Frontotemporal dementia (FTD) account for 2.6% of all-cause dementia. Though regarded as the most common presenile dementia, the incidence of FTD increased over time and peaked at the age of 75–79 [19, 20]. The age-standardized incidence of FTD was 2.90 per 100,000 person-year. Time ranges of survival changed slightly among bvFTD (behavioral variant of frontotemporal dementia) and AD, whereas FTD patients initially developing motor symptoms (all having PSP or CBD as underlying pathology) had the shortest survival time [19]. Accuracy of data about FTD is hampered by under-diagnosis and different criteria adopted. For better estimation, a multicenter prospective observational study designed in Europe is underway [21].

In Olmsted County, the incidence of PSP and CBS (corticobasal syndrome) increased over time, being 2.6 per 100,000 person-years and 0.4 per 100,000 person-years respectively [22], while another study found similar prevalence between them (around10.84/100,000) [23]. Most of patients are diagnosed at the age of 78 (70–74 for PSP, 75–79 for CBS [23]) with median survival time around 6 years [22].

AD is the most common type of dementia, accounting for 60–70% of all cases globally [19]. From 2010–2012, the prevalence was 14.7%, which remained steady since 1994 and was higher in low-income countries. However, the annual incidence dropped prominently from...
2.8% in 1998–2000 to 2.2% in 2010–2012 [24]. Another study observed a 13% decrease per decade over the past 25 years [25]. Additionally, in non-western countries, the incidence of AD rose significantly among groups aged between 65 and 74 [26].

AGD is commonly regarded as a late on-set disease with mixed pathology. In a non-Caucasian population, 15.2% of participants were diagnosed with AGD, whose mean age were 78.9 ± 9.4 years [27]. In younger population with potentially purer AGD pathology, a study

Fig. 1  MAPT pathological mutations in exons, haplotypes, and alternative splicing. MAPT (microtubule associated protein tau) gene, located on chromosome 17q21.3, has been identified with over 100 mutations, and pathological mutations associated with increased risk for tauopathies are shown above. The difference between H1 and H2 haplotypes is a 900 kb inversion existing in the largest linkage disequilibrium (LD) area in chromosome 17. Besides, H1 and its various sub-haplotypes usually contribute to disease occurrence, while H2 haplotype often act as a protective factor. Alternative splicing is common in neuronal cells which help to increase genetic plasticity and the diversity of proteome under physiological conditions [6]. However, imbalance in the ratio of the 3R and 4R isoforms can give rise to the pathogenesis of tauopathies, as the 4R tau is more efficient in promoting microtubule assembly with an extra repeat domain R2 which hyper-stabilize MT and more free-floating tau leads to aggregates formation [3, 6, 7]
identified 7 patients via postmortem examination, only 2 were female. Most patients died at 64 years old with median survival time being 3 months (0.5–36) [28].

The clinical and neuropathological diagnosis criteria of CTE [29] haven’t reached a consensus due to the small number of cases studied. Thus, the exact incidence of CTE is unknown [30]. It has been reported that CTE is unavoidable in some sports. One study found that CTE pathology was more common in athletes and was mainly observed in men [31]. American football was the sport most associated with CTE (OR: 2.62) [31]. Longer playing years or a higher level of professionalism were linked to an increased risk of CTE and pathology severity [32, 33]. Prospective, autopsy studies of populations from different exposure backgrounds are currently needed to confirm its epidemiology and public impacts [30, 31].

Clinical symptoms
Tauopathies lead to a variety of behavioral, movement, language, and memory deficits [34, 35] (see in Table 1). Though we classify these symptoms into categories, overlap is common. In a cross-sectional study comprising 310 patients with frontotemporal lobar degeneration (FTLD), 62% of participants met the diagnostic criteria for more than one syndrome [36]. Such high continuity in phenotypes challenges the current mode, which diagnoses patients as discrete syndromes [36].

FTD
FTD is an overall depiction of three clinical variants, including behavioral-variant frontotemporal dementia (bvFTD), non-fluent variant primary progressive aphasia (nfvPPA), and semantic-variant primary progressive aphasia (svPPA), which predominantly affect personality, behaviors, and language skills [37].

Overlap of three phenotypes is more prominent as disease deteriorates, and is consistent with pathology expansion to the large areas of frontal and temporal lobes. Motor disorder can also appear over time [36].

bvFTD can be diagnosed with neuropsychiatric symptoms and behavioral changes [38]. Criteria include a) early disinhibition (inappropriate manner and

| Table 1: Phenotypes of tauopathies and their salient features |
|---------------------------------------------------------------|
| **Phenotype** | **Salient features** |
|----------------|---------------------|
| Cognitive/behavioral disorders | |
| bvFTD | Behavioral variant of frontotemporal dementia |
| bvAD | Behavioral or dysexecutive variant AD |
| PSP-F | PSP with frontal presentation |
| PSP-RS | Richardson's syndrome |
| CBS | Corticobasal syndrome |
| PSP-CBS | PSP-corticobasal syndrome |
| Movement disorders | |
| PSP-P | PSP with parkinsonism |
| PSP-PGF | Progressive gait freezing |
| PSP-C | PSP with predominant cerebellar ataxia |
| PLS | Primary lateral sclerosis |
| Language disorders | |
| nfvPPA | Non-fluent/agrammatic variant of primary progressive aphasia |
| svPPA | Semantic variant of primary progressive aphasia |
| lvPPA | Logopenic variant of primary progressive aphasia |
| PPAOS | Primary progressive apraxia of speech |
| PSP-SL | PSP with predominant speech/language disorder |
| Amnestic symptoms | |
| aAD | Amnestic Alzheimer's disease |

Prominent episodic memory loss and deficits in speaking, visuospatial disorientation, and impaired executive abilities
irritability), b) apathy, which is similar to depression, c) loss of empathy, d) early compulsive, repetitive, or stereotyped behaviors, impaired executive abilities and e) eating pattern changes including varied preference and hyperorality [38–40]. nfvPPA shows labored speech, sound errors, and impaired grammar but still retains single-word comprehension and plain semantics. To the contrary, svPPA manifests anomia, impaired comprehension of single words and object knowledge, though grammar and speech fluency are spared.

**PSPS**

PSP syndromes (PSPS) encompass a range of behavioral, movement, and language disorders, among which PSP-RS (Richardson's syndrome)—a classic movement disorder—is most widely studied. However, an autopsy based retrospective research indicated that up to 60–75% of patients with PSP pathology showed nonclassical variant PSP phenotypes which are outlined below, suggesting neglect in previous studies [41].

Postural instability and ensuing frequent falls are early signs of PSP-RS. But the diagnostic feature—vertical supranuclear ophthalmoplegia—usually develops in the 7th year after onset, or never appears. Patients also show mild dementia, dysarthria, dysphagia, executive dysfunction and non-levodopa responsive parkinsonism (axial, symmetric akinetic-rigid syndrome, and extensor neck dystonia) [34, 42–44]. After the appearance of clinical symptoms, people tend to live for 6.9 years on average [43].

PSP with predominant parkinsonism (PSP-P) is considered the second most common phenotype in PSPS followed by PSP with corticobasal syndrome (PSP-CBS) according to a prospective study [45]. PSP-P can be easily misdiagnosed as PD in initial stages for their akin manifestations. Retrospective diagnosis is made when they develop PSP-RS related manifestations.

In patients diagnosed with PSP, the symptom of progressive gait freezing (PSP-PGF) occurs as early as the onset of disease and deteriorates during illness [44]. It's a pure movement deficit with no response to levodopa and can happen under specific circumstances or is a feature of PSP-RS [44].

PSP and CBS are clinically and genetically overlapping, as 44% of patients with CBS had PSP-like features and 30% of patients with PSP had CBS-like features [36]. PSP-CBS patients have PSP pathology and similar symptoms to CBS, including levodopa-resistant rigidity, bradykinesia, and apraxia. Clinical differentiation between PSP-CBS and CBD-CBS is thus impossible. When compared with PSP-RS, PSP-CBS has more severe ideomotor apraxia [45].

PSP-speech language (PSP-SL) phenotype depicts a syndrome which initially develops language disorders akin to nfvPPA before transformation into PSP-RS after years. PSP with frontal presentation (PSP-F) shows similar symptoms to bvFTD in early stages before developing motor dysfunctions like PSP-RS. Cerebellar ataxia appears at the onset of PSP with predominant cerebellar ataxia (PSP-C), but is not included in MDS PSP criteria [46].

**CBS**

The corticobasal syndrome (CBS) is characterized by asymmetrical limb apraxia, levodopa-resistant parkinsonism (dystonia, rigidity, tremor, and myoclonus) and deficits in higher cortical function [41, 47, 48]. Initial symptoms usually include cognition decline, meaning problems in vision, language, executive ability, and social cognition [47]. Another typical feature for CBS is alien/anarchic limb phenomena [49]. Other common symptoms include dysarthria and dysphagia.

Akin to PSP-RS, CBS shows equally severe abnormalities in movement involving limbs and eyeball [45]. Nonetheless, the description of freezing gait and myoclonus is lacking in the definition of PSP-RS, which are still the vital characteristics of CBS and PSP-PGF [45].

**CTE**

Apart from typical history of head injuries, CTE (chronic traumatic encephalopathy) is reported to have nonspecific symptoms including emotional disorders (depression, anxiety, irritability), bradykinesia, gait instability and cognition impairment. However, bias is inevitable as most studies were conducted retrospectively. Recently, the first prospective study comparing the clinical profiles of 6 CTE and 25 AD patients with autopsy evidence didn't find a distinct clinical phenotype from AD, showing similar performance in motor, neuropsychological, behavioral, and cognitive evaluations [50].

**AD**

Single or multidomain amnesia (also named aMCI, amnestic mild cognitive impairment) is the most common manifestation in early stages of typical AD (Alzheimer’s disease) [37, 51], in which patients’ ability to form new episodic memories is damaged while other functions are conserved [37]. Some symptoms might occur long time before diagnosis including depression, sleep pattern changes, apathy and severe anxiety [51]. Typical symptoms are more common in LOAD (late onset AD) patients.

In atypical AD, other than memory loss, abnormalities in language, visuospatial dysfunction, impaired behavior, and executive abilities tend to appear earlier,
and mostly happen in EOAD (early onset AD) population [37, 51]. Based on clinical features, atypical AD has been classified into three phenotypes, including logopenic variant primary progressive aphasia (lvPPA), which has anomia, fluency deficit, phonemic paraphasias and memory loss; posterior cortical atrophy (PCA), which has compromised advanced visual functions (visual field cuts, alexia, agnosia, ideomotor apraxia and cortically blindness) in early stages; and behavioral dysexecutive variant AD (bvAD), which can be misdiagnosed as bvFTD but shows milder behavioral dysfunction and earlier memory loss [37].

Pathology

3R tauopathy

**PiD**  PiD is unique among tauopathies in predominantly obtaining 3R tau isoforms [1]. The atrophy of cortex is usually asymmetrical and presents as a knife-edge appearance, mostly occurring in frontal and temporal lobes, resulting in enlargement of the ventricle [52, 53]. The atrophy of neostriatum is inconsistent [52]. Other brain areas involved in PiD include amygdala and hippocampus [52] (see pathologies in Table 2).

The orbicular, demarcated from cytoplasm, argyrophilic inclusions existing in neurons are typical features of PiD (named Pick bodies) [53]. Granule cells in the dentate gyrus of hippocampus are mostly affected [54]. Inclusions can also be found in pyramidal neurons and subcortical areas [52, 54]. Other pathology in PiD includes neuronal loss, gliosis, and ballooned neurons (or called Pick cells) [52, 54]. In glial cells, abnormal changes encompass thorn-shaped astrocytes and globular inclusions in oligodendrocytes [54].

4R tauopathy

**PSP**  PSP mainly consists of 4R tau isoforms, with prominent neuronal tau pathology in subcortical areas and astroglial tau in neocortex and striatum [55]. Characteristic atrophy tends to occur in subthalamic nucleus and brainstem, particularly in midbrain tectum and the superior cerebellar peduncle [56].

Most tau pathologies have been found in neurons forming globular neurofibrillary tangles. In astrocytes, tau aggregates as tufts and surrounds nuclei in the proximal processes [57]. These special cells are called tufted astrocytes and are regarded as a feature of diagnostic value.

| Neuropathology                  | Predominant tau isoform | Affected cell types | Affected brain areas                  | Pathology hallmarks                                      |
|---------------------------------|-------------------------|---------------------|---------------------------------------|----------------------------------------------------------|
| Pick’s disease                  | 3R                      | Neurons and glia    | Frontal lobes Temporal lobes           | Pick Bodies; Ballooned neurons/ Pick cells                |
|                                 |                         |                     | Neostriatum Limbic system              |                                                          |
| Corticobasal degeneration       | 4R                      | Neurons and glia    | Focal atrophy of superior frontal gyrus and parietal lobe | Pretangles; Astrocytic plaques (AP); Oligodendroglial coiled bodies (CB); Ballooned cells |
| Progressive supranuclear palsy  | 4R                      | Neurons and glia    | Basal ganglia Brainstem Diencephalon    | Globose neurofibrillary tangles (NFTs); Tufted astrocytes (TA); Oligodendroglial coiled bodies (CB); Neuronal threads  |
|                                 |                         |                     | Cortical regions                      |                                                          |
| Globular glial tauopathy        | 4R                      | Neurons and glia    | Frontal and temporal lobes Motor cortex Cerebral spinal tract | Globular oligodendrocytic incusions (GOIs); Globular astrocytic inclusions (GAI); Neuronal cytoplasmic inclusions (NCIs) |
| Argyrophilic grain disease      | 4R                      | Neurons and glia    | Anterior temporal lobe Amygdala        | Argyrophilic grains; Coiled bodies; Neuronal pre-tangles; Ballooned neurons; Granular /Fuzzy astrocytes |
|                                 |                         |                     | Ambient gyrus Hippocampus             |                                                          |
| Aging-related tau astroglialopathy | 4R                  | Astrocyte           | Subpial, subependymal, perivascular,   | Thorn-shaped astrocytes (TSA); Granular-fuzzy astrocytes |
|                                 |                         |                     | and white and grey matter areas       |                                                          |
| Chronic traumatic encephalopathy | 3R + 4R                | Neurons and glia    | Hippocampus Neocortex Brainstem        | Neurofibrillary tangles (NFTs); Astrocytic tangles       |
| Primary age-related tauopathy   | 3R + 4R                | Neurons             | Temporal lobes Basal forebrain Brainstem Olfactory bulb | Neurofibrillary tangles (NFTs)                          |
| Alzheimer’s disease             | 3R + 4R                | Neurons             | Neocortex Limbic regions              | Neurofibrillary tangles (NFTs); Amyloid plaques; Neuritc plaques |
for PSP [56]. Other pathologic characteristics involve coiled bodies in oligodendrocytes, depigmentation in substantia nigra, gliosis and neuronal loss [56]. Herein, the severity of gliosis is associated with NFTs (neurofibrillary tangles) accumulations [58]. In some areas, like striatum (especially globus pallidus), grey matter in cortex and white matter in cerebellum, the presence of tau pathology in glial cells (astrocytes and oligodendrocytes) may precede tau accumulation in neurons, which might reflect the characteristic spreading pattern of different subtypes [55].

CBD  In CBD, more severe pathology is found in the frontal part of brain, while PSP mostly affects the hindbrain areas [59]. Frontoparietal cortices, striatum, amygdaloid body and the substantia nigra are also influenced in CBD [52, 60].

Both CBD and PSP have 4R tau inclusions in astrocytes, coiled bodies in oligodendrocytes, and dense neuropil threads, but their tau deposits in astrocytes have distinct morphology. Tufted astrocytes in PSP and astrocytic plaques found in CBD are mutually exclusive and haven’t been found in the same brain [61]. Similar to PSP, astrocytes in CBD might be involved earlier than neuronal tau accumulation [61] which is the diagnostic characteristic of CBD patients [55]. Astrocytic plaques and neuritic plaques are independent concepts with no overlap, although they sound akin and similar in appearance [52]. Considerable affected astrocytes exist in regional cortex and neostriatum [52] and have been proved to be associated with synapse loss [60]. In neurons, tau deposits are mainly composed of pretangles and reacts poorly to antibodies targeting NFTs [1, 52]. Ballooned neurons have also been found in CBD especially in limbic regions and cortex, and their density in CBD is 30 times higher than that in PSP [1, 52].

AGD  AGD is a 4R tauopathy characterized by circumscribed asymmetric atrophy in anterior temporal lobe, amygdala, and ambient gyrus [62].

Argyrophilic grains (AGs) are associated with cognitive decline, mostly seen in ambient gyrus initially and medial temporal lobe in later stages [63]. Granular/fuzzy astrocytes (GFAs) are constantly present in amygdala. Other brain regions variably affected include putamen, caudate nucleus and frontal lobe [64]. GFAs are astrocytes with slight perinuclear tau deposits and bushy tau granules gathering at astrocytic processes [64]. Moreover, the analysis of 105 cases hypothesized that AGD pathology is the strongest predictor of the presence of GFAs in amygdala [64]. Coiled bodies and neuronal pre-tangles can also be detected in AGD [1].

GGT  Tau pathology in globular glial tauopathy (GGT) mainly contains 4R tau isoforms, predominantly existing in oligodendrocytes and astrocytes [65]. Tau accumulations in neurons are distinguished by their diffuse distribution in the cytoplasm, where they form globular, cord-like, or horseshoe-shaped inclusions [52, 66].

The globular astrocytic inclusions (GAI)s in GGT, according to consensus, are distinct from those in other tauopathies, such as astrocytic plaques in CBD and tufted astrocytes in PSP, and all these astrocytic pathologies can appear in GGT [67, 68]. Furthermore, GGT is the umbrella term for three pathological subtypes [67]. In type I, globular oligodendrocytic inclusions (GOIs) are predominantly present in frontotemporal regions, leading to behavioral symptoms. Minor coiled bodies in oligodendrocytes as well as GAI can also be found [67]. Movement is more heavily damaged in type II, where motor cortex and corticospinal tract are primarily affected [67]. Type III seems to be a combination of the two subtypes mentioned above, as frontotemporal lobes, motor cortex, anterior horn of the spinal cord and corticospinal tract are all involved [67–69]. Type III GGT has a higher burden and smaller size of GAI in the motor cortex than type II. The horseshoe-like tau inclusions in neurons are exclusively present in type III GGT [66].

ARTAG  Aging-related tau astrogliopathy (ARTAG) mainly consists of 4R tau isoforms. It is characterized by thorn-shaped astrocytes (TSA) (mainly existing in subpial, subependymal, perivascular, and white matter areas) and granular-fuzzy astrocytes (often in gray matter) [70]. Chronic brain trauma might induce tau astrogliopathy, implying a connection between CTE and ARTAG [70]. Besides, ageing is proved to be the most important etiology of ARTAG [71].

3R and 4R tauopathy

AD  AD obtains an equal amount of 3R and 4R tau in total and disproportional tau isoforms regionally [52]. NFTs and amyloid plaques remain as the typical characteristics, and tau-related pathology exists mostly inside neurons. NFTs are mature forms of pretangles (mainly in somas and dendrites), comprising insoluble twisted fibers of mixed 3R and 4R tau. The intraneuronal flame-shaped
NFTs can gradually become extracellular ghost tangles with reduced immunoreactivity [1].

Neuritic plaques, or senile plaques, are comprised of dystrophic neurites with tau pathology and extracellular Aβ deposits [72]. The Aβ deposition was found both in AD and cerebral amyloid angiopathy (CAA), suggesting a cross-talk between them [73]. Moreover, the research on relationship between neuritic plaques and cerebrovascular dysfunction have long focused on Aβ deposits [73]. The less discussed tau neurites were linked to compromise of the microvasculature in a recent study [72].

Furthermore, Aβ might accelerate tau deposits as more tau PET (positron emission tomography) tracers (18F-AV-1451) have been taken up by neurons with more amyloid accumulations [74]. A 7-year prospective study discovered a sequential occurrence of increase in Aβ, tau accumulation and cognitive decline, and the initial Aβ level was related to successive tau fluctuations and ultimate tau concentration [75]. Another study further indicated that the ratio of Aβ42/40, rather than total Aβ levels, plays a key role in the induction of NFTs [76].

In addition to morphological variations, a growing body of literature suggests a direct correlation between distinct tau fibril structures and neuropathological patterns, supporting the concept of tau strains (pathological conformations that linked to defined neuropathological patterns) [82]. Recently, a study proposed a classification based on disease-specific tau filament folds, providing a novel perspective complementary to clinical symptoms and autopsy study [83]. Further exploration of unique conformations of tau will assist in the selection of specific tau tracers and antibodies [82].

**Progression of tau pathology**

As disease deteriorates, tau pathology is hypothesized to sequentially invade wider areas of the brain, which is observed in animal models, autopsy samples (using immunohistochemical staining) and living people (using tau-PET). The propagation of tau is described as “prion-like”, due to its seeding (transforming normal tau into misfolded protein) and transmission properties, though lacking evidence of interpersonal infection. A growing body of literature suggests heterogeneity in propagation routes within one pathology, probably reflecting different phenotypes, and might imply differences in neuropathology and ensuing therapies. In this section, we briefly summarize generally accepted propagation patterns and their recent progress.

**PiD**

A four-stage sequential pattern for PiD pathology was proposed in 2016 based on neuropathological examination [84]. Tau deposits usually start from frontotemporal neocortex and limbic areas and move to subcortical regions, brainstem, motor cortex and finally the visual cortex [84] (Fig. 2A).

In early stages, discrepancies in areas of involvement exist between the bvFTD-PiD and the nfvPPA-PiD populations. bvFTD-PiD has tau pathology predominantly in prefrontal and temporal cortices, while nfvPPA-PiD mainly affects left inferior frontal, orbitofrontal and insula cortices [88]. Later, pathology in both groups spreads to motor areas and parietal lobes [88].

**AD**

A stereotype about the propagation of NFTs has been proposed as the six Braak stages, which ignores the individual variabilities. To improve the prediction of tau spread, a model was proposed based on tau-PET samples and hypotheses about tau spreading along neuronal connections (Fig. 2B) [85].

Moreover, adopting tau-PET tracer instead of histopathological staining, heterogeneity in spreading patterns...
was suggested by a study, comprising limbic-predominant phenotype, parietal-dominant and medial temporal lobe-sparing phenotype, predominant posterior occipitotemporal phenotype, and asymmetric temporoparietal phenotype, which might unify the propagation patterns of typical and atypical AD [89].

**CTE**

The tau pathology in CTE starts from neocortex and spreads to medial temporal lobe [78]. Gradually, neuronal and glial pathology will expand to extensive neocortical, brainstem and allocortical areas [77]. In 2013, based on the severity and distribution of hyperphosphorylated tau, McKee and colleagues divided the progression of pathology into four stages [87] (Fig. 2D). In a recent study, McKee staging scheme is consistent with higher scores of p-tau density, older age, and propensity for dementia, which proved its value in CTE research [79].

**PSP**

A recent study hypothesized that all PSP subtypes share one common site for the initial development of neuronal pathology, which is the pallido-nigroluysian axis [55]. Apart from neuronal tau, discrepancies in cell-specific tau distribution (especially tau deposits in astrocytes and oligodendrocytes) exist among different phenotypes, suggesting varying propagation routes and dynamics [55]. Analysis based on pooled cases ignoring clinical phenotypes suggests tau progression from subcortical areas to cortices [55] (Fig. 2C).

**AGD**

A four-stage theory depicting the chronological progression of AGs was proposed. Those brain areas include ambient gyrus as the initial site, temporal lobe, subiculum, entorhinal cortex, septum, insular cortex, and anterior cingulate gyrus [57] (Fig. 2E). In wildtype mouse models, after inoculating pure AGD pathology unilaterally in hippocampus, involvement of fimbria, bilateral corpus callosum and wider brain regions was observed, proving the seeding and spreading property of AGD tau [90].

**GGT**

Tau propagation in GGT type I is somewhat described, invading white matters in peri-amygdala and hippocampal regions initially, and expanding to limbic regions [57]. Reports about tau progression in GGT type II and III haven't been found.

**Clinicopathological correlations**

The clinical symptoms of tauopathies mainly imply brain regions developing pathology. However, anatomical and pathological overlap among tauopathies, as well as participation of other proteins, disrupts the consistent one-to-one match between clinical symptoms and underlying pathology. For example, in AD patients with pathology evidence, most of them show symptoms of AD, but they can also present as CBS, bv-FTD and nfv-PPA. In clinically diagnosed AD patients, apart from AD pathology, CTE, PART, PiD and AGD can also appear (Fig. 3).

**3R tauopathy**

**PiD** PiD shows symptoms of FTD, with bvFTD in the beginning and gradual impairment in social comportment and executive skills [84]. In a retrospective study analyzing 21 patients with Pick's disease as pathology, more than half of them showed symptoms like bvFTD (12/21), making it the most common one [53]. Less common manifestations include PPA (primary progressive aphasia) (7/21), CBS (1/21) and amnestic dementia (1/21) [53]. These presentations are in line with the brain areas that tend to be affected in PiD [52]. Besides, PiD patients presenting as bvFTD has faster rate in frontotemporal atrophy when compared with those having PPA manifestations [88].

(See figure on next page.)

**Fig. 2** Spatial-temporal distribution of tau lesions in schemes of brains. Deeper color means earlier involvement. **A** Tau progression in PiD has four stages, shown in medial and lateral views. Stage I, tau affects angular gyrus, limbic and frontotemporal regions. Stage II/III involves white matter tracts, subcortical structures (thalamus, striatum), serotonergic/noradrenergic brainstem nuclei, primary motor cortex and pre-cerebellar nuclei. Stage IV, tau invades visual cortex and cerebellar. Modified from [84]. **B** Tau progression in AD has six stages. Stage I/II, tau affect transentorhinal area. Stage III/IV, severe involvement of entorhinal, hippocampus and limbic areas happens. Stage V/VI, tau reaches primary and secondary neocortex. Modified from [85, 86]. **C** Tau progression in PSP has seven stages. Stage 0/I, pallido-luyso-nigral axis shows tau burden. Stage II/III, tau invades basal ganglia, dentate nucleus and pedunculopontine nucleus. Stage IV/V, tau reaches frontoparietal and temporal lobes. Stage VI/VI, occipital cortices, substantia nigra, subthalamus and globus pallidus are involved. Modified from [55]. **D** Tau progression in CTE has four stages, shown in coronal view at levels of genu of corpus callosum, mammillary body, and lateral geniculate body. Stage I/II, tau is restricted focally deep in the sulci of cortex, especially frontal lobe, surrounding small vessels and expand to superficial layers. Stage III, tau is widespread to cortices including frontal, temporal, parietal, and insular lobes. Meanwhile, amygdala, hippocampus, and entorhinal cortex are involved. Stage IV, tau affects most regions of cerebral cortex. Modified from [87]. **E** Tau progression (argyrophilic grains (AGs)) in AGD has four stages, shown in view same as D. Stage I is characterized by AGs in ambient gyrus, hippocampus (CA1), entorhinal and amygdala. Stage II shows involvement of medial temporal lobe and subiculum. Stage III, AGs reaches anterior temporal, cingulate gyrus, rectus gyrus, septum, accumbens nucleus, insular and orbitofrontal cortices, and hypothalamus (CA2 CA3). Stage IV involves neocortex and brainstem (not shown in figures). Modified from [63].
Fig. 2 (See legend on previous page.)


4R tauopathy

**AGD**  AGD is associated with ageing, lower income and eating disorders [27]. In a population aged 80 years or older, people with AGD pathology constitute more than half of it [52]. Even in a population with normal cognition, 31% of them might bear insidious AGD pathology, eliciting dispute about the pathogenetic role of AGD [27]. Coexistence with other pathologies is common. Overlaps with PSP, CBD, AD, PiD, PD, LBD (Lewy body dementia), etc. have been found [27, 52].

Clinicopathological correlations are not specific, which is confounded by normal ageing and concurrence of pathologies, resulting in difficulties of reaching antemortem diagnosis [52]. A retrospective study on 55 patients aged under 75 with relatively pure AGD pathology (low concurrence) concluded common symptoms for AGD patients: progressive cognitive impairment akin to the onset stage of AD, urinary incontinence, seizures, and psychological disorders [28].

**CBD**  Only 25–50% of CBD patients manifest as CBS. Apart from that, bvFTD, nfvPPA, AD, and Richardson’s syndrome also appear in CBD cases [61]. In patients with rapid progression (RP-CBD, disease duration is less than 3 years), rapid global cognitive impairment, CBS and Richardson’s syndrome are more common and are accompanied by advanced pathology (predominant neuronal tau deposits and nigral cell loss) [91]. By analyzing 210 cases from brain banks, CBS occupies 37.1% of CBD cases, followed by Richardson’s syndrome (23.3%), bvFTD (13.8%), AD-like dementia (8.1%) and nfvPPA (4.8%) [48].
A definite diagnosis needs specific biomarkers and genetic information. Thus, current clinical diagnostic criteria are relatively broad to obtain more possible cases [48].

**PSP**  The Movement Disorders Society PSP diagnostic criteria published in 2017 lists syndromes that possibly imply PSP pathology, which have already been mentioned in the previous part [92]. 24–50% of PSP patients manifest as PSP-RS, followed by PSP-P [57]. Primary lateral sclerosis showing upper neuron disorders is reported in rare cases [57].

Overlap with other pathology is common (especially with AD and AGD) but has little impact on disease progression [93]. Pathology also varies among different phenotypes. In a prospective study, PSP-CBS had the lowest score in semantic fluency test, followed by PSP-RS, implying the most severe damage to left inferior frontal and temporal cortex in both phenotypes [45]. Studies have found more involved glial cells in PSP-RS when compared with PSP-P. In the meanwhile, PSP-P exhibits more benign clinical progression [55]. A heavier burden of total tau in frontal and temporal neocortical neurons and white matter is more common in PSP-FTD when compared with PSP-RS [94].

**GGT**  According to the information from 88 GGT patients worldwide, the most common phenotypes for GGT are PPA (25%) and bvFTD (22.7%), less common ones include upper motor neuron disorders, amnesia, Richardson syndrome, parkinsonism and CBS, similar to phenotype composition in GGT with MAPT mutations [95].

Three GGT pathology subtypes are associated with varied phenotype spectrums which is consistent with typical affected brain regions, but is not enough for neuropathological differentiation [95]. Type I GGT predominantly presents as bvFTD due to damage in frontal and temporal lobes. Type II is characterized by upper neuron symptoms, including Richardson’s syndrome eliciting discussion about whether type II GGT belongs to atypical PSPs. Type III presents as a combination of type I and type II, involving bvFTD, movement disorders and extrapyramidal syndromes [95].

**3R and 4R tauopathy**

**AD**  Patients with AD pathology can manifest as heterogenous phenotypes, probably caused by comorbidity and regional vulnerability [96]. EOAD has more concomitant pathologies, which aligns with a lower cognitive score before death [97]. Furthermore, the presence of LBD is frequently associated with a faster decline in cognition [96]. Typical AD has damage primarily in limbic system and the medial temporal lobe, while PCA locates damage in occipitoparietal region and, in rare cases, the posterior temporal lobes [37].

NFT is a hallmark closely associated with AD’s manifestations. It is a better predictor of the severity of symptoms (especially cognition decline) and neuronal loss than amyloid beta peptide [3, 98]. Intriguingly, patterns of brain atrophy implied by tau deposits can precede and be identical to later detection by MRI and FDG-PET [99, 100]. Meanwhile, different AD phenotypes show higher NFT burden in specific brain regions. The superior temporal gyrus has more severe NFT pathology in lvPPA; in CBS, higher NFT burden is found in primary motor cortex; in visuospatial dysfunction, NFT tend to accumulate in angular gyrus and hippocampus (CA1 region) [96].

**CTE**  Clinical symptoms of CTE might largely depend on concomitant pathology [50]. Thus, CTE’s contribution to clinical manifestation is uncertain. It’s mostly accompanying other pathologies, or in fewer cases, the primary neuropathological change driving symptoms, or without clinical significance [101]. In a retrospective study, athletes with CTE pathology mainly received AD and vascular dementia as their clinical diagnosis [101].

The exacerbation of symptoms is associated with the progression of tau pathology. In stage I CTE, headache and distraction are most common. Amnesia and mood disorders happen in stage II. Impairment of cognition, executive function and visuospatial ability appear in stage III. At last, stage IV patients show dementia with short-term memory loss and mood disorders [87].

**Genetics**

What provokes the conversion from soluble disordered tau to insoluble misfolded deposits is still unknown, so does the mechanism by which tau leads to neurodegeneration. Studies in genetics offer a way to discover and understand potential pathophysiological processes.

**MAPT mutations**

In primary tauopathies, sporadic cases constitute the majority of the incidence. Only approximately 31% have been reported with family history [102], which is even lower in PSP and GGT [69]. Familial inheritance is usually in an autosomal dominant pattern in FTD and is associated with three different genes (C9orf72, GRN, or MAPT), of which MAPT occupies 5–10% [21, 102]. While in secondary tauopathies, including AD, myotonic
dystrophy, Down syndrome, etc., no pathogenic MAPT mutation has been found.

Currently, over 50 mutations in the MAPT gene have been correlated with neurodegenerative diseases [2]. In r14510 mice, overexpression of tauP301L leads to NFTs accumulation, memory disorders, rapid neuronal loss, and brain atrophy in early stages [103]. Possessing more than one mutated site on the MAPT gene might have additive effects, as expressing tau with two mutations (P301L and S320F) in CNS led to severe tangle pathology, neuroinflammation and memory deficits than tau with a single mutation [104]. Some pathogenic MAPT mutations are shown in Fig. 1. Missense mutations are most common, followed by silent or nonsense mutations and duplicates or deletions.

In sporadic and familial PSP, MAPT is the strongest genetic risk factor. More than 15 mutations have been identified [105]. In GGT, MAPT mutations include N296H, R5H, K317M, K317N and P301L, mainly distributing in exon 10 and its flank [69]. In the CBS population, MAPT is the second most common risk gene, and mutations are all missense variants [106].

A growing body of literature elucidates the downstream effects of tau mutations, including enhanced tau aggregation, dysfunction in mRNA splicing and tau structure alteration [7].

MAPT mutations usually happen in the carboxy-terminus where microtubule binding domains (MTBDs) exist. Thus, the binding affinity of tau is often impaired, resulting in microtubule destabilization and tau aggregation [102]. Unlike most MAPT mutations, Q336H and Q336R in exon12 enhanced MT-tau binding and reduced phosphorylation of tau, but still led to increased seeding propensity, tau aggregation and risk for PiD [7, 107]. In this condition, hyper-stabilization of MT and other molecular mechanisms might contribute to pathology [7, 107].

Besides, multiple exonic and intronic variants within and around exon 10 can impact splicing of pre-mRNA (E10 exclusion: ΔK280, G272V; E10 inclusion: N279, L284I, S285R and c.823-10G > T) [108]. Consequent unequal ratio of 3R and 4R tau isoforms might generate more free-floating tau monomers, which will enhance tau aggregation [3, 4, 7].

In regions far from MTBD, the role of mutations is not clearly elucidated. A shift of alanine to threonine at codon 152 in MAPT might confer a new phosphorylation site, leading to impaired MT binding, disordered retrograde axon transport and an increased risk for primary and secondary tauopathies [109].

**MAPT polymorphisms and haplotypes**

The largest linkage disequilibrium (LD) block on chromosome 17 contains MAPT gene and comprises two haplotypes (H1 and H2) [110, 111]. 3 million years ago, the H2 haplotype was generated through a 900 kb inversion from H1 and only appears in the Caucasian population [110–112].

In CBD and PSP, the H1 haplotype is overexpressed and has been verified as the strongest genetic risk factor [59, 108, 112]. Meanwhile, specific sub-haplotypes of H1 that contribute to tauopathies need further elucidation [111].

A case–control study involving 802 autopsy verified PSP patients has discovered that H1d (OR: 1.86), H1g (OR: 3.64) and H1o (OR: 2.60) could lead to the onset of PSP [111], and H2, H1c, H1e, H1q and H1d are related to the severity of tau pathology [111].

As PSP and CBD share overlapped genetic risk background [59], similar haplotypes including H1d (OR: 1.76) and H1c (OR: 1.49) also appear to be risk factors for CBD, but they can’t predict or influence the severity of pathology or course of disease [59]. In contrast, H2 is associated with a lower risk of disease (OR: 0.26) [59].

The association between MAPT haplotypes and AD is inconsistent in previous researches [110]. Recent studies have described the H2 haplotype as playing a protecting role in the occurrence of LOAD (OR=0.90) [113]. A stratification analysis comprising 4124 AD and 3290 healthy controls concluded that the H1 haplotype mildly increased risk for AD only in people without APOE ε4 [114], as the contribution of the H1 haplotype to disease risk might be covered up by APOE ε4 in its carriers.

Increased expression of MAPT, especially 4R tau isoforms, is associated with the H1 haplotype, being 1.5 times more than that in the H2 haplotype [113]. Such amount of tau accelerates the toxicity of Aβ and formation of tau oligomers in drosophila, leading to an increased propensity for LOAD [113]. While the H2 haplotype, exhibiting protective effect in most cases, can reduce the alternative splicing of E10, generating more 3R tau isoforms [2].

**Risk loci beyond MAPT**

To date, GWAS (Genome Wide Association Study) studies have identified more than 10 genes contributing to the risk of PSP. LRRK2 is a relatively rare cause, and is highly associated with PD [105]. A SNP (single nucleotide polymorphism) rs2242367 in LRRK2 was recently proved to be highly correlated with survival of PSP patients [43]. The mutation upregulated lncRNA (LINC02555) and influenced the expression of LRRK2 [43]. The relationship between MOBP, STX6 and P53, proposed by the largest GWAS of PSP to date [115], was confirmed again recently in a European population [116]. By analyzing associations between PSP latent traits and risk SNPs, a study identified 16 new candidate genes (SPTBN5,
EHD4, SEC13, ATP2B2, etc.) that potentially correlated with PSP pathophysiology [117].

In addition, the intronic variant rs564309 in TRIM11 is more common in non-RS phenotypes [105]. TRIM11 helps to degrade misfolded proteins via UPS (ubiquitin-proteasomal system) [105] and variant rs564309 can thus lead to increased NFTs but doesn’t influence glial pathology [118].

In a systematic review of 58 reported CBS cases, GRN was the most common genetic risk factor, followed by C9ORF72, PRNP, GBA and MR52/ZHX2 [106]. CBD and PSP have many risk genes in common, including MOBP, CXC4, EGFR, GLDC and VEGF. A combination of MAPT and CXC4 increases the risk of PSP, while the presence of MAPT, MOBP, and GLDC increases the susceptibility to CBD or FTD [106]. In the first research exploring associations between mitochondrial DNA (mtDNA) and susceptibility to PSP and CBD, mtDNA sub-haplotype H4 contributed to an increased risk of CBD, and haplotype HV/HV0a can be a marker for PSP pathophysiology as it corresponded with decreased neuropil threads [119].

APOE ɛ4, APP, PSEN1, and PSEN2 are well-known in Alzheimer’s disease. Apart from that, a recent meta-analysis identified new causal genes, including CCDC6, TSPAN14, NCK2, SPRED2, BIN1, PH1B, PTK2B, PILRA, and CASS4 [120]. In a genetic meta-analysis, risk loci for LOAD concerning tau protein and APP metabolism were confirmed, showing shared genetic consequences as EOAD with autosomal dominant variant [121]. These new risk genes were IQCK, ACE, ADAM10, ADAMTS1, and WWOX, and they also affected immunity and lipid metabolism in this study [121].

APOE ɛ4 is a well-established risk factor for AD and decreases survival in a dose-dependent manner, while APOE ɛ2 significantly reduces the risk of developing AD [122]. The relationship between APOE and atypical parkinsonism is controversial. Previous research regarded APOE ɛ2 as a risk factor for PSP, AGD [57]. However, a recent study hasn’t found significant associations between APOE and the risk of PSP or CBD [122].

Further work focusing on functions of risk loci is important as most of them locate in noncoding regions [123, 124]. Recently, the employment of machine learning in integrating the multi-omic framework offered an approach to predict noncoding variants’ functions [123]. In another research, 27 top risk loci for AD altered the expression of 21 adjacent genes. Seven SNPs (particularly in INPP5D, PTK2B) were linked to tau aggregation, 11 SNPs (in ADAM10, IGHV1-68, SLC24A4/RIN3, etc.) were linked to amyloid pathology and 8 SNPs (especially in ECHDC3, HS3ST1) were linked to neurodegeneration [124].

**Tau biomarkers**

In recent years, advancement has been made concerning in vivo detection of tau, which mainly consist of neuroimaging, cerebrospinal fluid, and blood markers. They are auspicious candidates for early and differential diagnosis, disease progression prediction, pharmacodynamic reflections, therapy mechanism interpretation [125] and trials participants selection [126]. At the same time, autopsy studies are also needed to validate sensitivity and specificity of biomarkers and detect concomitant pathology. Moreover, various tau related biomarkers have been explored more thoroughly in Alzheimer’s disease [127], while many non-AD tauopathies still don’t have commonly accepted tau related biomarkers [128, 129].

**CSF and blood tau**

**CSF biomarker** CSF t-tau can reflect neuronal injury and is common in various neurodegenerative diseases. CSF p-tau has stronger correlations with pathologic state [130] and CSF p-tau181 (tau phosphorylated at threonine 181) is exceedingly specific for AD, which facilitates differential diagnosis.

However, during the progression of AD, increases in CSF p-tau217 (tau phosphorylated at threonine 217) are significantly higher than CSF p-tau181, suggesting a better performance of CSF p-tau217 in the diagnosis of early and advanced stages of AD [131]. Another study found a stronger association between CSF p-tau217 and PET imaging of tau and amyloid. Since amyloid is specific for AD, p-tau217 allows for a more accurate distinction between AD and non-AD tauopathies (like FTLD) [132]. In addition, CSF p-tau181 and p-tau217 show subtle differences when acting as prognostic markers predicting cortical thickness [133].

Other phosphorylated tau proteins are also promising biomarkers. CSF p-tau235 increases early during the course of AD, and the presence of CSF p-tau235 and CSF p-tau231 follows sequential phosphorylation incidence, which can be used in the staging of early phases [134]. However, CSF t-tau and p-tau decreased in PSP patients compared with healthy control, and lower baseline p-tau was associated with more rapid progression of disease, suggesting a different tau pathogenesis from AD [135].

Tau 368 is a tau protein fragment ending in amino acid 368. It increases in the brain tissues of AD patients, constituting tangles. Thus, the ratio of CSF tau 368/t-tau decreased in all AD cohorts in a study, reflecting tangle pathology [136].
As an axonal protein, CSF neurofilament light (NfL) chain is a non-specific biomarker for neurodegeneration. It is associated with cingulum and corpus callosum FA (fraction anisotropy) and WMH (white matter hyper-intensities) in MRI [137]. In AD patients, CSF NfL correctly identified more AD cases than CSF t-tau [138]. In FTLD patients with autopsy evidence, CSF NfL increased and showed higher accuracy than t-tau in differentiating FTLD pathology from normal participants and AD, even in the context of co-pathology [138].

The development of 4R-tau-specific CSF biomarkers is currently underway. By adapting the ultrasensitive tau seed amplification assay (4R RT-QuIC), a study analyzed CSF from living people and postmortem samples diagnosed as PSP and CBD, and identified three 4R tau seeds associated with diseases [139], which needs further validation. Such method was also applied to detect 3R and 3R/4R tau aggregates in AD, CTE and PiD [140].

CSF biomarkers have limitations such as high cost, limited availability, and invasive quality [126, 141]. Hence, research on blood-based biomarkers covering p-tau18, p-tau217, plasma NfL, etc. provides a rosy future [142].

**Plasma biomarker**

As a biomarker specific for AD, plasma p-tau181 can discriminate AD from healthy controls and FTLD efficiently [143, 144]. Although it can't predict disease progression alone [145], higher p-tau181 is associated with the conversion of MCI to AD and cognitive decline [143].

Plasma p-tau217 helps to differentiate AD from other neuropathological diseases (like FTLD), with a higher accuracy than plasma p-tau181 [146], plasma NfL, and MRI measures and shows almost equal efficacy compared with CSF p-tau and tau-PET [142]. Higher baseline p-tau217 levels can predict disease progression independently (exacerbation in brain atrophy, tau deposits and cognition decline), even outperforms CSF biomarkers [145]. But p-tau217 failed to act as a prognostic tool in non-AD tauopathies [145]. Furthermore, the ability to distinguish between normal and abnormal tau PET imaging made p-tau217 a possible replacement for tau PET when it didn't take into account regional deposits [142, 146].

P-tau biomarkers are promising tools for preclinical diagnosis as phosphorylation precedes aggregation. A study found an increase of CSF and plasma p-tau181, CSF p-tau217 and CSF p-tau231 in pre-symptomatic stages of AD, which is useful in further clinical trials on early-stage AD patients [147]. Another study found plasma p-tau217 increases before the tau-PET signal [125], with performance in early diagnosis close to CSF p-tau [142]. Moreover, a combination of plasma p-tau, APOE genotyping and cognitive test can accurately predict AD diagnosis in the subjective cognition decline and MCI population [148].

The level of NfL in plasma is highly associated with CSF NfL and varies rapidly around the onset of symptoms in AD patients [149]. It can imply neuronal damage [126] and monitor neurodegeneration and disease progression [149]. In addition, NfL is a potential biomarker for non-AD tauopathies. Plasma NfL increases in FTLD and can differentiate FTLD from healthy controls and AD patients, with better performance than plasma t-tau [150]. Another study found NfL in serum along with cognitive screening could differentiate PD from PSP and CBS [41].

Despite the advancement, the accuracy of biomarkers in plasma might be affected by dilution, peripheral alterations including degradation by liver and kidney, and disturbed by peripheral analogous proteins when compared with evaluation in CSF [126, 151].

**PET**

In 2020, a first-generation tau tracer [18F]-flortaucipir (AV1451) was authorized as assistance for evaluations of NFTs in AD by the US Food and Drug Administration [2]. Recently, the significant correlation between 18F-AV1451 and NFTs distribution has been proved again in a study comparing tau PET imaging with postmortem assessment (sensitivity: 94.7%, specificity: 50.0% [152]). 18F-AV1451 can reflect advanced tau pathology in AD and is more relevant to dynamic clinical changes [153], but it failed to detect early pathology formation as CSF p-tau does [154], and didn't reliably predict tau pathology in non-AD patients [154], suggesting its use mainly in the neuropathological diagnosis of AD [155]. In preclinical stages of AD, BPND (binding potential) of 18F-AV1451 subtly elevated in MAPT mutation carriers (especially R406W) compared to controls, suggesting its use as an early prediction for MAPT mutations that lead to 3R/4R tauopathies [156]. Similar phenomenon was observed in FTD patients with Q351R MAPT mutation [157]. 18F-AV1451 uptake can more accurately predict cognition decline and neurodegeneration in AD than CSF p-tau [153], while another study found CSF p-tau elevation preceding 18F-AV1451 positivity during cognition decline [155]. Moreover, researchers have found uptake of this tracer in FTLD with TDP-43, raising the controversy about the specificity of 18F-AV1451 for tau pathology, especially when used in FTLD patients [158].

[18F]-JNJ-067 is also exceedingly selective for AD and barely binds tau protein in healthy controls, MCI population [159]. This quality offers a chance to use [18F]-JNJ-067 in
differentiating AD from healthy seniors and other tauopathies [159]. Its use in the early clinical phase is limited due to insufficient sensitivity to differentiate healthy controls and MCI [159].

$[^{18}F]$RO948 and $[^{18}F]$MK6240 perform better in AD patients. A study only found retention of $[^{18}F]$RO948 in AD cases and R406W mutation carriers when compared with MCI and other neuropathological diseases, suggesting use for differentiation [160]. Intriguingly, for $[^{18}F]$AV1451, $[^{18}F]$RO948 and $[^{18}F]$MK6240, tracer uptake in the temporal lobe (with similar cut-offs around 1.35 SUVR) is a common feature for differentiating AD from healthy seniors and non-AD tauopathies [161]. What’s more, $[^{18}F]$MK6240 has got a higher dynamic range than $[^{18}F]$AV1451, which is promising in detecting earlier pathologies [162].

In non-AD tauopathies, tau tracers usually show an absent-to-low binding level, and development is underway. $[^{18}F]$PM-PBB3, derived from $^{11}$C-PBB3, was more stable and thus elevated the sensitivity of detecting deposits, especially in FTLD tauopathies, which possess fewer fibrillar aggregates than AD [163]. Compared with 3R/4R tauopathies, $[^{18}F]$PI-2620 is less stable when binding to 4R tau in CBS and PSP, but shows different uptake patterns in cortices, supporting its role in differentiation [164]. $[^{3}H]$CBD-2115 shows higher affinity for 4R tau than $[^{18}F]$MK6240 and $[^{18}F]$AV1451 in PSP and CBD, and further improvement will focus on BBB (blood–brain barrier) penetration and binding affinity [165].

At present, off-target is still a problem existing in all tau tracers to varying degrees. The elevation of specific binding is useful in accurate quantification. Multiple qualities are suggested for ideal tracers: higher dynamic range, lower off-target incidence, steadiness, and higher consistent reliability [159].

**Targeting tau therapeutics to tauopathies**

**Microtubule stabilization**

Tau binds to the outer surface of microtubules (MT), prompting the addition of tubulins to MT and stabilizing its structure [166]. In tauopathies, hyperphosphorylation of tau leads to reduced binding affinity, resulting in destabilization of the MT and ensuing axonal deficit and tau pathology [10] (see therapies in Fig. 4).

The first investigated MT stabilizer was paclitaxel, whose initial research was about its anti-tumor property. The poor quality of crossing BBB terminated its further study afterward [167].

Recently, two parallel, double-blind, placebo-controlled randomized clinical trials on TPI-287 (abeotaxane) showed less tolerability among AD patients (more hypersensitivity reactions) than patients with PSP and CBD [168]. Moreover, no relief in symptoms was observed [168].

EpoD (Epothilone D) is a microtubule stabilizing agent. In 2020, a study first treating APP/PS1 mice with EpoD (BMS-241027) concluded that, apart from alleviating axonal/synaptic damage, neurite dystrophy, and neuronal loss, EpoD was also able to reduce amyloid accumulations [169]. However, the phase 1 clinical trial treating AD has been terminated probably due to adverse effect [170].

**CNDR-51657**, a drug belonging to triazolo-pyrimidines, binds to tubulin at the same site as vinblastine [171]. When administered orally to 9-month female PS19 mice, microtubule defects, axonal dystrophy, as well as tau pathology were significantly relieved [171]. No adverse effects were reported. Moreover, triazolo-pyrimidines have already been investigated as anticancer agents. The advantages of good brain penetration and oral bioavailability have made them promising candidates for MT stabilizers [172].

**Inhibition of tau aggregation**

During disease, tau proteins experience abnormal aggregation, shifting from monomers to NFTs. Therefore, inhibiting aggregation has the potential to alleviate illness. But the pathogenic and toxic tau forms still need further identification, which complicates the strategies targeting tau aggregation.

Methylene blue (MB), a brain penetrable molecule, can inhibit the aggregation of tau in vitro by blocking interaction between tau proteins and influencing the stability of PHFs (paired helical filaments) [173]. But two phase 3 clinical trials of LMTX (TRx0237), a drug derived from MB, demonstrated no significant benefit [174]. Another phase 3 trial showed no differences in prespecified outcomes between two plans (200 mg/day or 8 mg/day) in the bvFTD population [175]. Recently, a randomized, double-blind, placebo-controlled phase 3 trial testing LMTX on AD patients is underway (Table 3). A study explained the poor efficacy of LMTX: although tau aggregation in vitro was attenuated under the treatment of MB, atomic force microscopy discovered an increase in granular tau oligomers, which are more toxic [176], while tau fibrils were reduced [177]. However, the soluble tau oligomers in P301L mice were reduced under the...
Fig. 4 (See legend on previous page.)
treatment of MB in another study, avoiding cognition decline [178]. Further exploration, such as adopting the BiFC (bimolecular fluorescence complementation) strategy in P301L mice, which realized in vivo investigation of soluble tau oligomers for the first time [178], is needed to elucidate the mechanism. ACI-3024 is reported to inhibit tau aggregation in cultured neurons and P301L mouse models. Meanwhile, microglia activation and neuronal loss were also reduced [179]. A phase 1 study in healthy volunteers has been done, but no registry entry or published work can be found.

CLR01 has leading effects among molecular tweezers (MTs), which are broad-spectrum protein aggregation inhibitors. In P301S-tau mice, CLR01 was shown to reduce tau aggregation, hyperphosphorylation and oligomerization [180]. No clinical trials have been conducted.

Table 3  Planned or ongoing clinical trials involving tau therapeutics

| Drug               | Mechanism of action                      | Disease       | Phase | ClinicalTrials.gov identifier   |
|--------------------|------------------------------------------|--------------|-------|---------------------------------|
| TRx0237            | Tau aggregation inhibitor                | AD           | III   | NCT03446001                     |
| IONIS MAPTRx       | Antisense oligonucleotide               | Mild AD      | I & II| NCT03186989                     |
| NicO752            | Antisense oligonucleotide               | PSP          | I     | NCT04539041                     |
| Fasudil            | Activation of autophagy                 | PSP, CBD     | II    | NCT04734379                     |
| Rapamycin          | Activation of autophagy                 | MCI, AD      | II    | NCT04629495                     |
| ACI-35.030         | Tau targeted vaccines                   | AD           | I     | NCT04445831                     |
| JACI-35.054        | Tau targeted vaccines                   | AD           | II    | NCT04445831                     |
| GV1001             | Tau targeted vaccines                   | Moderate AD  | II    | NCT03959553                     |
| LY3303560          | Passive immunotherapy                   | AD           | II    | NCT03518073                     |
| E2814              | Passive immunotherapy                   | AD           | I & II| NCT04971733                     |
| UCB0107            | Passive immunotherapy                   | AD           | II    | NCT04867616                     |
| ACI-35.030         | Tau targeted vaccines                   | PSP          | I     | NCT04658199 NCT04185415        |
| RO7105705          | Passive immunotherapy                   | AD           | II    | NCT03828747                     |
| ABBV-8E12          | Passive immunotherapy                   | AD           | II    | NCT03712787                     |
| Lu AF87908         | Passive immunotherapy                   | AD           | II    | NCT04149860                     |
| JNJ-63733657       | Passive immunotherapy                   | AD Cognitive Dysfunction | II   | NCT04619420                     |
| LY3372689          | O-GlcNAcase enzyme inhibitor            | AD           | II    | NCT05063539                     |
| ASN51              | O-GlcNAcase enzyme inhibitor            | AD           | I     | NCT04759365                     |
| Lithium Carbonate  | GSK-3β inhibitor                        | FTD          | II    | NCT02862210                     |
| Tolfenamic acid    | CDK5 and GSK-3β inhibitor               | PSP          | I/II  | NCT04253132                     |
| AZP2006            | Increases progranulin levels, decreases tau phosphorylation | PSP          | II    | NCT0408355                      |
| Salsalate          | Tau acetylation inhibitor               | AD           | I     | NCT03277573                     |
| tDCS               | NIBS                                     | AD           | NA    | NCT04855643                     |
| tTMS               | NIBS                                     | AD MCI       | NA    | NCT04294888                     |
| Sodium Oligomannate Capsules | Anti-inflammation                    | AD           | IV    | NCT05058040                     |
| JNJ-40346527       | Anti-inflammation                       | AD MCI       | I     | NCT04121208                     |
| VX-745             | Anti-inflammation                       | AD           | II    | NCT03435861                     |
| NE3107             | Anti-inflammation                       | AD           | III   | NCT04669028                     |
| Dasatinib & Quercetin | Senolytic treatment                    | MCI, AD      | I & II| NCT04785300                     |
|                   |                                          | EOAD MCI     | II    | NCT04685590                     |
|                   |                                          | AD           | I & II| NCT04063124                     |
|                   |                                          | AD           | II    | NCT04784416                     |
|                   |                                          | AD           | II    | NCT04780399                     |
|                   |                                          | AD           | II    | NCT03282916                     |

AD Alzheimer’s disease, CBD corticobasal degeneration, PSP progressive supranuclear palsy, MCI mild cognitive impairment, FTD frontotemporal dementia, NA Not Applicable, EOAD early-onset AD
A platform based on recombinant hyperphosphorylated tau realized high-throughput screening for potentially effective compounds. In the results, p-tau aggregation was suppressed by drugs including R-(-)-apomorphine and raloxifene, while benzodiazepines were risk factors for pathology formation [181]. It provides a novel assay for screening effective medicine while identifying risk factors [181].

**Regulation of post-translational modifications**

Phosphorylation, acetylation, glycation, methylation, sumoylation and truncation of tau are post-translational modifications that can occur [34].

Hyperphosphorylated tau tends to self-assemble into PHFs or straight filaments and further becomes oligomers in the cytosol affecting microtubule stabilization. Therefore, drugs targeting related kinases (CDK5, GSK3β, and JNK) and phosphatases (PP2A) have long been under development. Sodium selenate activated PP2A by reducing the inert demethylated catalytic subunit [182]. A 3-month supplement of sodium selenate in THY-Tau22 mice rehabilitated cognition deficits due to neuron damage [182]. A phase 1b clinical trial of sodium selenate on 15 patients with possible bvFTD achieved some therapeutic effects, but a larger placebo-controlled study is required for further confirmation [183].

Acetylation of tau mostly occurs in the fibril-forming core, which facilitates the stacking of β-strand, reducing the solubility of tau [184]. Salsalate works as an anti-inflammatory drug. Meanwhile, the level of tau acetylation decreased at K174 when treating PS19 mice with salsalate, preventing memory loss and hippocampal atrophy [185]. However, an open-label phase 1 clinical trial of salsalate in patients diagnosed as PSP-RS showed no therapeutic effect [186]. No access to the result has been published.

O-GlcNAcylation describes a process adding O-GlcNAc (O-linked β-N-acetylglucosamine) to serine and threonine residues, acting as a protective role against tauopathies. Thus, reducing deglycosylation of tau by inhibiting O-GlcNAcase (OGA) enzyme is a feasible treatment. MK-8719, an OGA inhibitor, reduced tau pathology and retarded brain atrophy in rTg4510 mouse models by improving glycosylation level [187]. Both MK-8719 and ASN120290 received orphan drug designation to treat PSP, but no clinical trial has been reported since then. Two clinical trials on LY3372689 and ASN51 are in progress (Table 3), but no formal preclinical studies are available.

**Reduction of tau expression**

Recently, an innovative antisense oligonucleotides (ASOs) molecule targeting MAPT exon4 successfully downregulated MAPT RNA expression by 96% in cells and reduced the tau protein level by 74% [188]. ASO’s effect has also been proved in several studies [189, 190]. Similar techniques include microRNA (miRNA), small interfering RNA (siRNA) and other transcription inhibitors [10]. A randomized, double-blind, placebo-controlled phase 2 clinical trial of a MAPT-targeting ASOs named Ionis-MAPTrx is conducting (Table 3).

Using AAV-delivered zinc finger protein transcription factors (ZFP-TFs) in mice has also reduced the expression of MAPT at the transcriptional level and alleviated neuronal damage [191]. Moreover, a modified AAV CRISPR-Cas9 construct, which could cross the blood–brain barrier, selectively disrupted the mutated APP allele in the whole brain of mice, resulting in a 6-month relief [192]. Such method may also apply to the MAPT gene.

**Regulation of exon 10 splicing**

The levels of 3R and 4R tau isoforms are approximately equal in healthy adult brains, and disturbance between them is hypothesized to elicit tau pathology [6]. Adjusting the ratio is hence a plausible treatment.

ASOs have long been used to interfere with genetic expression. Apart from degrading targeted mRNA in a DNA-RNA duplex through activated RNase-H, which is mentioned above (9.4 reduction of tau expression), ASOs can also adjust splicing through knocking down mutations disrupting normal splicing pattern, or directly modulating splicing by competing with cis-acting elements and trans-acting proteins [6] like the exon skipping therapy applied in Duchenne Muscular Dystrophy.

Another method which can alter isoform composition is trans-splicing. In htau mouse models, an abnormal ratio between 3 and 4R isoforms was associated with motor coordination impairment. By shifting 3R tau to 4R tau through trans-splicing in early stages, tau isoforms reached an equal proportion without changes in total tau content and motor disorders were relieved [193]. It should be noted that, htau mice obtain nonmutated six tau isoforms like humans, but produce an excess of 3R tau. In humans, therapies tend to reduce exon 10 inclusion and thus reduce pathological 4R tau in some primary tauopathies. An RNA-targeting CRISPR system also corrected the abnormal splicing in neuron models of FTD, providing a supplement to RNA engineering tools [2].

**Increase of tau clearance**

The degradation of pathological proteins has various mechanisms, which mainly include UPS and autophagy-lysosome pathway (ALP), whose function is impeded when tau accumulates in mouse and human brain [194, 195]. Stimulating these pathways is thus a plausible method to cope with tau deposits.
As a highly conservative serine-threonine kinase which decreases autophagic activity, mTOR inactivation through siRNA significantly alleviated tau aggregation in mouse models [196]. The preclinical value of rapamycin, an mTOR kinase inhibitor, is supported by animal experiments. However, rapamycin might only work in the earliest stages of AD [197]. Indeed, two ongoing clinical trials (phase 2 and phase 1) test rapamycin on MCI and early AD patients (Table 3). Besides, by screening a group of small molecules, a study confirmed three competitive mTOR kinase inhibitors, including OSI-027, AZD2014 and AZD8055, all of which demonstrated higher efficacy than rapamycin [194].

Ubiquitination increases protein degradation via lysosome or proteasome. In the P301L mouse model, knockdown of USP13, a de-ubiquinating enzyme, resulted in a lower level of p-tau and increased tau clearance, probably due to autophagy [198]. Possible therapies should target UPS components like USP14, UCHL1, E3 enzyme, PINK1, Parkin and USP30 [199].

Apart from activating autophagy, methods such as directly stimulating lysosome activity and interfering with tau degradation via the endoplasmic reticulum are also viable [200].

**Tau immunization**

Failures in the development of anti β-amyloid immunotherapies elicited the trend of targeting tau pathology through active or passive immunization methods.

**Vaccinations** Vaccines in active immunization comprise immunogen and various adjuvants. Immunogen options include human full-length tau, PHF-1, phosphorylated tau peptide, truncated and N-terminal regions of tau [201]. IgG was found in the brains of wildtype and transgenic mice treated with AV1980R/A and AdvaxCpG, which are immunogen containing phosphatase activating domains and strong adjuvants respectively [202]. Such treatment also ameliorated tau hyperphosphorylation, especially at Ser396, and improved memory dysfunction [202].

Two vaccines including AADVac1 and ACI35 as the immunogens are under development [201]. DC8E8, which is an efficient antibody targeting microtubule binding domains (MBD) of tau protein, acts as the prototype for AADVac1. A randomized, placebo-controlled, double-blind, parallel-arm, multicenter phase 2 study of AADVac1 on mild AD dementia patients proved its safety but suggested no obvious impact on cognition tests [203].

ACI-35 is a synthetic antigen composed of 16 amino acids (Tau393–408) with phosphorylation at residues S396 and S404 [201]. ACI-35 mainly targets the C-terminal region of tau protein, especially the pS396 epitope and conformational differences, showing a higher affinity for pathologic tau [204]. The employment of this liposome-based vaccine in P301L mice successfully induced antibodies and reduced the soluble tau phosphorylated at S396 in the forebrain and brainstem [205]. A phase Ib/IIa clinical trial is conducted on AD patients in early stages (Table 3).

Antibodies induced by immunogens can reduce misfolded tau protein more efficiently compared with direct antibody treatment [201]. But the immune effect is not sustained and varies between populations, different doses, delivery methods and adjuvants [201]. Possible side effects comprise immune tolerance after persistent stimulation and autoimmune diseases [201].

**Tau antibodies** Based on the prion-like tau propagation hypothesis, most antibodies tested in clinical trials are IgG4, targeting extracellular tau in transmission [86]. Antibody D (murine equivalent of UCB0107), targeting a central epitope on tau, was shown to effectively block tau transfer between neurons [206]. However, the involvement of exosomes in tau spreading [207] and the fact that intracellular tau constitutes most of the tau pathology, emphasize the necessity of targeting tau inside neurons. A study confirmed the higher efficacy of intracellular targeting in rTg4510 mouse models, as two intrabodies (CP13i and PHF1i, targeting intracellular tau) alleviated tau pathology while scFv (single-chain variable fragments, targeting extracellular tau) showed no therapeutic effect [208].

The therapeutic effect of antibodies is also influenced by epitope selection. Antibodies recognizing central part of tau showed higher efficacy than antibodies targeting amino terminus in cultured neurons and animal models [206]. More specifically, binding MTBD from residues 224–369 showed better results in inhibiting tau transmission [179].

ABBV-8E12 (tilavonemab) and BIIB092 (gosuranemab), which bind tau at the N-terminal side, failed to show efficacy in PSP patients in two phase 2 clinical trials [209, 210]. However, decreased CSF free tau and accumulation of tau in lysosomes of emerging perivascular vesicular astrocytes proved that the binding happens as anticipated [209, 211]. Reasons for futility in clinical trials include difficulties in earlier diagnosis of PSP, especially preclinical stages, noneffective epitopes and extracellular targeting [210]. A phase 2 clinical study testing ABBV-8E12 on AD patients is underway (Table 3). An increasing number of antibodies are under development, shown in Table 3.
Immune modulators and other therapeutic approaches

Immune modulators A growing body of literature indicates that chronic activation of the immune system, including glial cells (especially microglia), complement, cytokines, inflammasomes and reactive oxygen species, can contribute to tau pathology exacerbation, apoptosis, and neurodegeneration in AD and primary tauopathies [212–214]. Further evidence suggested that peripheral innate immunity might increase the risk of dementia, while adaptive immunity is linked to a decreased risk of dementia [215]. Microglia are regarded as major players in neuroinflammation. PET analysis in living people revealed that microglia network was associated with tau propagation [216]. They also serve as mediators for some environmental risk factors and lifestyle choices that contribute to dementia [212]. Furthermore, neuroinflammation is potentially associated with disease heterogeneity in pathology, clinical manifestation, and disease severity [217, 218]. However, relationship between immunity and tauopathies is a vast topic, beyond the scope of this review. The interested reader is directed to previous work [212, 219–221]

Sodium Oligomannate Capsules (GV-971) is a marine-derived oligosaccharide, targeting various mechanisms including reconstituting intestinal bacteria which facilitates infiltration of immune cells from the periphery to the brain. In the phase 3 clinical trial just finished, prominent cognitive improvement was observed with no significant adverse effect [222]. A phase 4 trial of GV-971 on Alzheimer’s disease is underway (Table 3).

JNJ-40346527 (JNJ-572), a selective inhibitor of CSF1R, suppressed the proliferation of microglia, neuronal loss, and attenuated behavioral disorders in ME7 prion and P301S mice [223]. A phase 1 study on AD and MCI is in the planning (Table 3).

NE3107 can selectively inhibit inflammatory mediators stimulated by ERK- and NF-κB, without influencing their homeostatic functions [224]. A phase 3 study is planned to examine its safety and efficacy in AD patients (Table 3).

NLRP3 is a kind of pattern recognition receptor. As a part of innate immunity, it combines with ASC to form the NLRP3 inflammasome under stimulation inside microglia [225]. It then activates IL-1β and IL-18 and can lead to cell death (termed “pyroptosis”) [212, 221]. Apart from participating in Aβ cascade inducing tau hyperphosphorylation [225], the NLRP3-ASC axis can be activated by aggregated tau, and in turn exacerbates tau pathology in mice [226]. Lack of NLRP3 inflammasome function ameliorated tau pathology and spatial memory deficits in another study [225]. NT-0796 is reported to selectively inhibited NLRP3 inflammasome, and a phase 1 study on healthy volunteers is underway, testing its safety and tolerability [227], but no registry entry or published work can be found.

What's more, activating specific inflammatory pathways might also be protective. A Plcγ2-P522R knock-in mouse model showed enhanced phagocytosis in microglia [228]. Another study observed the interaction between astrocytes and microglia through IL-3 and IL-3Ra, which stimulated microglia and ameliorated AD pathology [229].

Other approaches Senescent astrocytes downregulated glutamate and potassium transporters, which led to neuronal death and neurodegeneration [230]. When exposed to extracellular tau, oxidative stress response and activation of inflammasome developed in astrocytes, contributing to cellular senescence and neurodegenerative diseases [231]. Hence, senolytic drugs which clear senescent cells by inducing apoptosis are feasible candidates for dealing with neurodegenerative disease. Clinical trials about dasatinib and quercetin on MCI, AD and EOAD patients are underway (Table 3).

NIBS (non-invasive brain stimulation), encompassing transcranial Magnetic Stimulation (tMS) and transcranial Direct Current Stimulation (tDCS), offers another solution. tMS and tDCS help to improve brain function through exciting pivotal brain areas [232]. A comprehensive summary of published evaluations of the response to NIBS in different neurodegenerative diseases is available in a recent review [232].

Conclusion Epidemiology study can also provide insights into disease formation, such as a worth noting decline in incidence of dementia, whose underlying causes might inspire novel disease understanding and treatment.

Manifestation and pathology overlap of tauopathies has led to lack of one-to-one match between symptoms and pathology. Further study on tau ultrastructure and heterogeneity in tau propagation might provide new perspectives for clinicopathological correlations, also aiding the development of specific ligand for tracers and disease-modifying therapies.

Exploration of biomarkers is active nowadays, reflecting the unmet need, especially in non-AD tauopathies and preclinical diagnosis. Emerging works are comparing
in vivo binding of biomarkers with neuropathological assessment to confirm their efficacy. Powerful blood-based biomarkers especially plasma p-tau217 and p-tau181, which can more accurately distinguish between AD and FTLD, are recommended to be used in screening and participants selection in clinical trials.

Significant underdiagnosis and misdiagnosis have been found in previous researches, which will mislead our understanding and further direction. Combing genetic information, imaging, and other biomarkers, as well as revising diagnostic criteria and implementing with high quality are important in diagnosis.

Failures to translate results from mouse models into clinical outcomes can be attributed to both preclinical studies and clinical trials, as well as the consistency in intervention stages. Moreover, targeting at early stages of tauopathies is a shared feature in recent trials. And a long-term cohort study comprising large population with detailed outcome and survival information will greatly subserve the discovery of pathogenic factors and novel effective therapeutic targets. Possible development in therapeutics might involve implementation of high-throughput screening, restoring tau physiological role and exploring new targets that highly associated with pathology.

Abbreviations

CSF: Cerebrospinal fluid; P.D: Pick's disease; PSP: Progressive supranuclear palsy; CBD: Corticobasal degeneration; AGD: Argyrophilic grain disease; AD: Alzheimer's disease; MAPT: Microtubule associated protein tau; CTE: Chronic traumatic encephalopathy; pre-mRNA: Precursor messenger RNA; MTBDs: Microtubule binding domains; FTD: Frontotemporal dementia; bvFTD: Behavioral variant of frontotemporal dementia; CBS: Corticobasal syndrome; FTLD: Frontotemporal lobar degeneration; nMAPPA: Non-fluent variant primary progressive aphasia; svPPA: Semantic-variant primary progressive aphasia; vPPA: Logopenic variant primary progressive aphasia; PSPS: PSP syndromes; RS: Richardson's syndrome; PSP-P: PSP with predominant parkinsonism; PSP-C: PSP with corticobasal syndrome; PSP-PGF: PSP with predominant gait freezing; PSP-SL: PSP with predominant speech or language disorder; PSP-F: PSP with frontal presentation; PSP-C: PSP with predominant cerebellar ataxia; LOAD: Late onset AD; EOAD: Early onset AD; PCA: Posterior cortical atrophy; bvAD: Behavioral dysexecutive variant AD; NFT: Neurofibrillary tangles; AGs: Argyrophilic grains; GFAs: Granular/fuzzy astrocytes; GGT: Globular glial tauopathy; GAlS: Globular astrocytic inclusions; GOSs: Globular oligodendrocytic inclusions; ARTAG: Aging-related tau astrogliopathy; TPA: Thororn-shaped astrocytes; Aβ: Amyloid beta; PART: Primary age-related tauopathy; PPA: Primary progressive aphasia; LBD: Lewy body dementia; LD: Linkage disequilibrium; GWAS: Genome Wide Association Study; UPS: Ubiquitin proteosomal system; mtDNA: Mitochondria DNA; NFl: Neurofilament light; FA: Fraction anisotropy; WWMH: White matter hyperintensities; p-tau217: Tau phosphorylated at threonine 217; p-tau181: Tau phosphorylated at threonine 181; MCI: Mild cognitive impairment; MT: Microtubules; MB: Methylene blue; A50s: Antisense oligonucleotides; ALP: Autophagy-lysosome pathway; PHFs: Paired helical filaments; NIBS: Non-invasive brain stimulation; TMS: Transcranial Magnetic Stimulation; TDCS: Transcranial Direct Current Stimulation.

Acknowledgements

Not applicable.

Authors’ contributions

JTY contributed to the conception and the structure of the manuscript; YZ did the literature search, led the writing of the manuscript, devised all the figures and tables and edited the manuscript. KMW and LY participated in the writing of the manuscript and helped to revise. JTY substantially revised and edited the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by grants from the National Natural Science Foundation of China (91849126), Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01) and ZHANGJIANG LAB, Tianqiao and Chrissy Chen Institute, and the State Key Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Not applicable.

Received: 31 December 2021 Accepted: 23 March 2022 Published online: 07 April 2022

References

1. Gotz J, Halliday G, Nisbet RM. Molecular Pathogenesis of the Tauopathies. Annu Rev Pathol. 2019. https://doi.org/10.1146/annurev-pathm echnics-012418-012936.

2. Sexton C, Snyder H, Beher D, Boxer AL, Brannelly P, Brion JP, Buée L, Cacace AM, Chételat G, Citron M, et al. Current directions in tau research: Highlights from Tau 2020. Alzheimers Dement. 2021. https://doi.org/10.1002/alz.12452.

3. Xia Y, Sorrentino ZA, Kim JD, Strang RH, Riffe CJ, Giasson BI. Impaired tau-microtubule interactions are prevalent among pathogenic tau variants, arising from missense mutations. J Biol Chem. 2019. https://doi.org/10.1074/jbc.RA119.010178.

4. Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019. https://doi.org/10.1038/s41374-019-0197-x.

5. Fischer I, Baas PW. Resurrecting the Mysteries of Big Tau. Trends Neurosci. 2020. https://doi.org/10.1016/j.tins.2020.04.007.

6. Li D, McIntosh CS, Mastaglia FL, Wilton SD, Aung-Htut MT. Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies. Transl Neurodegener. 2021. https://doi.org/10.1186/s40035-021-00240-7.

7. Xia Y, Nasif L, Giasson BI. Pathogenic MAPT mutations Q336H and Q336R have isofrom-dependent differences in aggregation propensity and microtubule dysfunction. J Neurochem. 2021. https://doi.org/10.1111/jnc.15358.

8. Gonçalves RA, Wijesekara N, Fraser PE, De Felice FG. Behavioral Abnormalities in Knockout and Humanized Tau Mice. Front Endocrinol (Lausanne). 2020. https://doi.org/10.3389/fendo.2020.00124.

9. Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics. Acta Neuropathol. 2020. https://doi.org/10.1007/s00401-020-02196-w.

10. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016. https://doi.org/10.1038/nrn.2015.1.

11. Xia Y, Prokop S, Gorion KM, Kim JD, Sorrentino ZA, Bell BM, Manaedis AN, Chakrabarty P, Davies P, Giasson BI. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer’s disease and other tauopathies. Acta Neuropathol Commun. 2020. https://doi.org/10.1186/s40478-020-00967-w.

12. Tracy TE, Madero-Pérez J, Swaney DL, Chang TS, Moritz M, Konrad C, Ward ME, Stevenson E, Hüttenhain R, Kauwe G, et al. Tau interactome...
therapeutic approaches. The Lancet Neurology. 2017. https://doi.org/10.1016/S1474-4422(17)30157-6.

47. Peterson KA, Patterson K, Rowe JB. Language impairment in progressive supranuclear palsy and corticobasal syndrome. J Neurol. 2021. https://doi.org/10.1007/s00415-019-09463-1.

48. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013. https://doi.org/10.1212/WNL.0b013e318270df1d.

49. Albrecht F, Mueller K, Ballarini T, Lampe L, Diehl-Schmid J, Fassbender K, Fliessbach K, Jahn H, Jacobi R, Kassubek J, et al. Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex. 2019. https://doi.org/10.1016/j.cortex.2019.02.015.

50. LoBue C, Schaffert J, Cullum CM, Peters ME, Didehbani N, Hart J, White A, Atri A. The Alzheimer’s Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019. https://doi.org/10.1016/j.mcna.2018.10.009.

51. Dugger BN, Dickson DW. Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017. https://doi.org/10.1101/cshperspect.a028035.

52. Choudhury P, Schafel ER, Paolini MA 2nd, Graft-Radford J, Alden EC, Machulda MM, Jones DT, Fields JA, Murray ME, Graft-Radford NR, et al. Pick’s disease: clinicopathologic characterization of 21 cases. J Neurol. 2020. https://doi.org/10.1007/s00415-020-09927-9.

53. Kovacs GG. Tauopathies. Handb Clin Neurol. 2017. https://doi.org/10.1016/B978-0-12-802395-2.00025-0.

54. Briel N, Pratsch K, Roeber S, Arzberger T, Herms J. Contribution of the subcortical white matter to the pathogenesis of progressive supranuclear palsy and corticobasal syndrome. J Neurol. 2021. https://doi.org/10.1007/s00415-019-09414-w.

55. Svenningsson P. Corticobasal degeneration. J Neuropathol Exp Neurol. 2008. https://doi.org/10.1097/NEN.0b013e318178a80f.

56. Tanaka H, Toyoshima Y, Kawakatsu S, Kobayashi R, Yokota O, Terada S, Kuroda S, Murata T, Higuchi Y, Otsu H, et al. Morphological characterisation of giall and neuronal tau pathology in globular glial tauopathy (Types II and III). Neurodegeneration. 2020. https://doi.org/10.1159/130339878.

57. Ahmed Z, Bigio EH, Budka H, Dickson DW, Ferrer I, Ghebret, Giacone G, Hatanpaa KJ, Holton JL, Josephs KA, et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol. 2013. https://doi.org/10.1007/s00401-013-1171-0.

58. Enro ME, Zelaya MV, Mendoza M, Larumbe R, Orteaga-Cubero S, Lanciego JL, Lladó A, Cabada T, Tuñón T, García-Bragado F, et al. Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings. J Neurol. 2019. https://doi.org/10.1007/s00415-019-09144-w.

59. Ferrer I, Andrés-Benito P, Zelaya MV, Aguirre MEE, Carmona M, Ausín K, Lachen-Montes M, Fernández-Ingoyog J, Santamaría E, Del Rio JA. Familial globular glial tauopathy linked to MAPT mutations: molecular neuropathology and seeding capacity of a prototypically mixed neuronal and glial tauopathy. Acta Neuropathol. 2020. https://doi.org/10.1007/s00401-019-01229-9.

60. Bachstatter AD, Garrett FG, Jicha GA, Nelson PT. Space-occupying brain lesions, trauma-related tau astrogliopathy, and ARTAG: a report of two cases and a literature review. Acta Neuropathol Commun. 2021. https://doi.org/10.1186/s40478-021-01152-3.

61. Kovacs GG, Ferrer I, Grimbler LT, Auzafouzett I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghebret, et al. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016. https://doi.org/10.1007/s00401-015-1509-x.

62. Hansira GK, Popov G, Banaczeck PO, Vogliaris M, Jategaonkar T, Goldsbury CS, Cullen KM. The neurotic plaque in Alzheimer’s disease: perivascular degeneration of neuronal processes. Neurobiol Aging. 2019. https://doi.org/10.1016/j.neurobiolaging.2019.06.009.

63. Greenberg SM, Backsiai BJ, Hernandez-Guillamón M, Prazin J, Sperling R, van Veluwe SJ. Cerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathways. Nat Rev Neurol. 2020. https://doi.org/10.1038/s41582-020-00565-x.

64. Shen XN, Xiao D, Li QJ, Tan CC, Cao XR, Tan L, Yu JT. MAPT rs242557 variant is associated with hippocampus tau uptake on (18F)-AV-1451 PET in non-demented elders. Aging (Albany NY). 2019. https://doi.org/10.18632/aging.101783.

65. Hansseu EB, Betensky RA, Jacobs HH, Schultz AP, Sepulcre J, Becker VE, Stein TD, Dickson DW, McKee AC. Tau isoforms are differentially associated with risk, severity of tau pathology, and clinical features. Acta Neuropathol Commun. 2020. https://doi.org/10.1186/s40478-020-01097-z.

66. Briel N, Pratsch K, Roebel S, Arbogster T, Herms J. Contribution of the astrocytic tau pathology to synaptic loss in progressive supranuclear palsy and corticobasal degeneration. Brain Pathol. 2021. https://doi.org/10.1111/bpa.12914.

67. Cherry JD, Kim SH, Stein TD, Pothast MJ, Nicks R, Meng G, Huber BR, Mez J, Alosco ML, Tripodis Y, et al. Evolution of neuronal and glial tau isoforms in chronic traumatic encephalopathy. Brain Pathol. 2020. https://doi.org/10.1161/01.01.000000000000707.

68. Cherry JD, Ennaught CD, Baumbach ZH, Tripodis Y, Huber BR, Alvarez VE, Stein TD, Dickson DW, McKee AC. Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer’s disease. Acta Neuropathol Commun. 2021. https://doi.org/10.1186/s40478-021-01189-4.

69. Alosco ML, Cherry JD, Huber BR, Tripodis Y, Baumbach Z, Kowall NW, Saittie N, Goldstein LE, Katz DJ, Dwyer B, et al. Characterizing tau deposition in chronic traumatic encephalopathy (CTE): utility of the McKee CTE staging scheme. Acta Neuropathol. 2020. https://doi.org/10.1007/s00401-020-01212-7.

70. Humphrey WC, Martinez-R, Pendell BB, Dwyer XW, McKee AC. Primary age-related tauopathy (PART) in the general autopsy setting Not just a disease of the elderly. Brain Pathol. 2021. https://doi.org/10.1111/bpa.12919.

71. Jellinger KA. Primary age-related tauopathy (PART) and Alzheimer’s disease (AD). Alzheimers Dement. 2019. https://doi.org/10.1016/j.jalz.2019.01.005.
82. Vaquer-Alicea J, Diamond MJ, Joachimiak LA. Tau strains shape disease. Acta Neuropathol. 2021. https://doi.org/10.1007/s00401-021-02301-7.
83. Shi Y, Zhang W, Yang Y, Murzin AG, Falcon B, Kotecha A, van Beers M, Tarutani A, Kametani F, Garringer HJ, et al. Structure-based classification of tauopathies. Nature. 2021. https://doi.org/10.1038/s41586-021-02306-6.
84. Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, Hpekper M, Hwang JH, Miller ZA, Huang EJ, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease. Brain. 2021. https://doi.org/10.1093/brain/awab099.
85. Ossenkoppele R, Leuzy A, Cho H, Sudoe CH, Strandberg O, Smith R, Palmqvist S, Matsumoto-Carlson N, Olsson T, Jogi J, et al. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-020-09599-w.
86. Singleton E, Hansson O, Pijnenburg YAL, La Joie R, Mantyh WG, Tideeman P, Stomrud E, Leuzy A, Johansson M, Strandberg O, et al. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2021. https://doi.org/10.1136/jnnp-2020-325497.
87. Lee EB, Kinch K, Johnson VE, Trojanowski JQ, Smith DH, Stewar W. Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. Acta Neuropathol. 2019. https://doi.org/10.1007/s00401-019-02030-y.
88. Caroppi P, Pironi S, Maderna E, Grisoli M, Rossi G. New MAPT variant in a FTD patient with Alzheimer’s disease phenotype at onset. Neurol Sci. 2021. https://doi.org/10.1007/s10072-020-04901-9.
89. Machacek M, Benzewski K, Forster K, Kemper L, Hyltonak C, Funrow E, Ashe KH, Koob MD. Factors other than hTau overexpression that contribute to tauopathy-like phenotype in 7tg4510 mice. Nat Commun. 2019. https://doi.org/10.1038/s41467-019-10428-1.
90. Koller EJ, Gonzalez De La Cruz E, Machula T, Ibanez RR, Lin WL, Williams T, Riffle CJ, Ryu D, Strange KH, Liu X, et al. Combining F301L and 320F tau variants produces a novel accelerated model of tauopathy. Hum Mol Genet. 2019. https://doi.org/10.1093/hmg/ddz151.
91. Wen Y, Zhou Y, Jiao B, Shen L. Genetics of Progressive Supranuclear Palsy: A Review. J Parkinsons Dis. 2021. https://doi.org/10.3233/jpd-202302.
92. Anenti F, Lazzeri G, Vizzello M, Monfrini E, Bresolin N, Saetti MC, Picillo M, Franco G, Di Fonzo A. Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review. Cells. 2021. https://doi.org/10.3390/cells1010171.
93. Siano G, Micaelli M, Scarlatti A, Querciolli V, Di Primio C, Cattaneo A. The Q336H MAPT Mutation Linked to Pick’s Disease Leads to Increased Binding of Tau to the Microtubule Network via Altered Conformational and Phosphorylation Effects. Front Mol Neurosci. 2020. https://doi.org/10.3389/fnmol.2020.00101.
94. Olszewka DA, Fearon C, McGuigan C, McVeigh TP, Houlden H, Polke JM, Lawlor BC, Coen R, Hutchinson M, Hutton M, et al. A clinical, molecular genetics and pathological study of a FTD-17 family with a heterozygous splicing variant c.823+1G>T at the intron 9/exon 10 of the MAPT gene. Neurobiol Aging. 2021. https://doi.org/10.1016/j.neurobiolaging.2021.05.010.
95. Butler VJ, Salazar DA, Soriano-Castell D, Alves-Ferreira M, Dennissen FJA, Vohra M, Oses-Prieto JA, Li KH, Wang AL, Jing B, et al. Tau/MAPT disease-associated variant A152T alters tau function and toxicity via impaired retrograde axonal transport. Hum Mol Genet. 2019. https://doi.org/10.1093/hmg/ddy442.
96. Strickland SL, Reddy JS, Allen M, N’Songo A, Burgess JD, Corda MM, Ballard T, Wang X, Carrasquillo MM, Biernacka JM, et al. MAPT haplotype-stratified GWAS reveals differential association for AD risk variants. Alzheimers Dement. 2020. https://doi.org/10.1002/alz.12099.
97. Heckman MG, Brennan RR, Labbé C, Soto AI, Koga S, DeTure MA, Murray ME, Petersen RC, Boeve BF, van Gerpen JA, et al. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurol. 2019. https://doi.org/10.1001/jamaneurol.2019.0250.
98. Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, et al. Novel tau filament fold in corticobasal degeneration. Nature. 2020. https://doi.org/10.1038/s41586-020-2043-0.
99. Miguel L, Frebourg T, Campion D, Lecourtès M. Moderate Overexpression of Tau in Drosophila Exacerbates Amyloid-β-Induced Neuronal Phenotypes and Correlates with Tau Oligomerization. J Alzheimers Dis. 2020. https://doi.org/10.3233/jad-190906.
100. Sánchez-Juan P, Moreno S, de Rojas I, Hernández I, Valero S, Alegría M, Montreuil L, García González P, Lage C, López-García S, et al. The MAPT H1 HaploType is a Risk Factor for Alzheimer’s Disease in APoE e4 Non-carriers. Front Aging Neurosci. 2019. https://doi.org/10.3389/fnagi.2019.00327.
115. Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011. https://doi.org/10.1038/ng.859.

116. Chen Z, Chen JA, Shatunov A, Jones AR, Kravitz SN, Huang HY, Lawrence L, Lowe JK, Lewis CM, Payan CAM, et al. Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Mov Disord. 2019. https://doi.org/10.1002/mds.27702.

117. Kouri N, Murray ME, Reddy JS, Serie DJ, Soto-Beasley A, Allen M, Carrasquillo MM, Wang X, Castanedes MC, Baker MC, et al. Latest trait modeling of neurofilamentopathies in progressive supranuclear palsy. Acta Neuropathol. 2021. https://doi.org/10.1007/s00401-021-02289-0.

118. Valentino RR, Koga S, Heckman MG, Brushaber DE, Diehl NN, Walton RL, Dickson DW, Ross OA. Association of Tripartite Motif Containing 11 ns564509 With Tau Pathology in Progressive Supranuclear Palsy. Mov Disord. 2020. https://doi.org/10.1002/mds.28010.

119. Valentino RR, Tamayaka N, Heckman MG, Johnson PW, Soto-Beasley AI, Walton RL, Koga S, Uitti RJ, Wozolek ZK, Dickson DW, Ross OA. Association of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures. Acta Neuropathol Commun. 2020. https://doi.org/10.1186/s41467-020-00315-2.

120. Schwartzentruber J, Cooper S, Liu JZ, Barrio-Hernandez I, Bello E, Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Sabir MS, Blauwendraat C, Ahmed S, Serrano GE, Beach TG, Perkins M, Corces MR, Shcherbina A, Kundu S, Gloudemans MJ, Frésard L, Granja Tan MS, Yang YX, Xu W, Wang HF, Tan L, Zuo CT, Dong Q, Tan L, Suckling J, Coughlin DG, Litvan I. Progressive supranuclear palsy: Advances in research. Acta Neuropathol. 2020. https://doi.org/10.1002/ajn.21994.

121. Barthélemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, Gabelle A, Lehmann S. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alzheimers Res Ther. 2020. https://doi.org/10.1186/s13195-020-00596-4.

122. Janelidze S, Stromrud E, Smith R, Palmqvist S, Mattsson N, Arey DC, Proctor NJ, Chai A, Snörenberg S, Sims JR, et al. Cerebrospinal fluid p-tau121 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun. 2020. https://doi.org/10.1038/s41467-020-15463-0.

123. Meliek MM, Aaker JA, Algerias-Schimmich A, Proctor NK, Machulda MM, Eichenlaub U, Knopman DS, Vemuri P, Graff-Radford J, Jack CR Jr, et al. Comparison of CSF phosphorylated tau181 and 217 for cognitive impairment with normal aging. Alzheimers Dis Int. 2021. https://doi.org/10.1155/2021/12415.

124. Lantero-Rodriguez J, Snellman A, Benedet AL, Milá-Alomá M, Camporesi E, Montoliu-Gaya L, Ashton NJ, Vrillon A, Kariaki TK, Gispert JD, et al. P-tau235: a novel biomarker for staging preclinical Alzheimer’s disease. EMBO Mol Med. 2021. https://doi.org/10.15222/emmm.202115098.

125. Rojas JC, Bang J, Lobach IV, Tsai RM, Rabkovich GD, Miller BL, Boxer AL. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018. https://doi.org/10.1212/ WNL.0000000000004859.

126. Blennow K, Chen C, Cigcigona C, Wildsmith KR, Manser PT, Bohorquez SMS, Zhang Z, Xie B, Peng J, Hansen O, et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for ringle pathology. Brain. 2020. https://doi.org/10.1093/brain/awaa234.

127. Mielke MM, Przybelski SA, Lesnick TG, Kern S, Zetterberg H, Blennow K, Knopman DS, Graff-Radford J, Petersen RC, Jack CR Jr, Vemuri P. Comparison of CSF phosphorylation light chain, neurogranin, and tau to MRI markers. Alzheimers Dement. 2021. https://doi.org/10.1016/j.alz.2022.02.007.

128. Cousins KAQ, Phillips JS, Irvin DJ, Lee EB, Wolk DA, Shaw LM, Zetterberg H, Blennow K, Burke SE, Kinney NG, et al. ATN incorporating cerebrospinal fluid phosphorylation light chain detects frontotemporal lobar degeneration. Alzheimers Dement. 2021. https://doi.org/10.1016/j.alz.2022.02.007.

129. Saijo E, Metrick MA 2nd, Koga S, Parchi P, Litvan I, Spina S, Boxer A, Rojas JC, Galasko D, Kraus A, et al. 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol. 2020. https://doi.org/10.1007/s00401-019-02080-2.

130. Metrick MA 2nd, Ferreire NDC, Saijo E, Kraus A, Newell K, Zanusso G, Vendruscolo M, Ghetti B, Caughey B. A single ultrasensitive assay for detection and discrimination of tau aggregates of Alzheimer and Pick diseases. Acta Neuropathol Commun. 2020. https://doi.org/10.1186/s41467-020-00867-z.

131. Przybelski SA, Lesnick TG, Kern S, Zetterberg H, Blennow K, de Silva R, Litvan I, Riley DE, et al. Identification of common variants finds MAPT duplications in progressive supranuclear palsy. Acta Neuropathol. 2020. https://doi.org/10.1007/s00401-021-02289-0.

132. Desai P, Evans D, Dhana K, Aggarwal NT, Wilson RS, McNichin E, Rajan KB. Longitudinal Association of Total Tau Concentrations and Physical Activity With Cognitive Decline in a Population Sample. JAMA Netw Open. 2021. https://doi.org/10.1001/jamanetwopen.2021.20398.

133. Palmqvist S, Janelidze S, Quirzo YT, Zetterberg H, Lopera F, Stromrud E, Su Y, Chen Y, Sensano GE, Leuzy A, et al. Discriminative Accuracy of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2021. https://doi.org/10.1001/jamaneurol.2020.4201.

134. Simrén J, Yu JT. Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. Alzheimers Res Ther. 2021. https://doi.org/10.1186/s13195-021-00755-7.

135. Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, Stromrud E, Palmqvist S, Mattsson-Carlsgen N, Hanson O. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2021. https://doi.org/10.1001/jamaneurol.2020.4201.

136. Simrén J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, Mattsson-Carlsgen N, Scholl M, Meoccio P, Vellas B, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement. 2021. https://doi.org/10.1001/alz.2021.12283.

137. Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iacurriano L, Cobigo Y, Heuer H, Spina S, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020. https://doi.org/10.1038/s41591-020-0762-2.

138. Pereira JB, Janelidze S, Stromrud E, Palmqvist S, van Westen D, Dage JL, Mattsson-Carlsgen N, Hanson O. Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain. 2021. https://doi.org/10.1093/brain/awab163.

139. Thijssen EH, La Joie R, Strom A, Fonseca C, Iacurriano L, Wolf A, Spina S, Allen IE, Cobigo Y, Heuer H, et al. Plasma phosphorylated tau 217 and phosphorylated tau181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021. https://doi.org/10.1016/S1474-4422(21)00214-3.

140. Suárez-Calvet M, Karikari TK, Ashton NJ, Lantero-Rodriguez J, Milá-Alomá M, Gispert JD, Salavado G, Mingollon C, Faura K, Shekari M, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the...
initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med. 2020. https://doi.org/10.15252/emmm.202019291.

148. Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Dale J, Stromqvist E, Iannelidze S, Mattsson-Carlgren N, Hansson O. Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021. https://doi.org/10.1038/s41591-021-01348-z.

149. Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Graber S, Kuder-Buleta E, LaFougere C, Laske C, et al. Serum neurofilament lightlines in neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019. https://doi.org/10.1038/s41591-018-0304-3.

150. Illán-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, Grinberg LT, Spina S, Kramer JH, Ramos EM, et al. Plasma Tau and Neurofilament Light in frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology. 2021. https://doi.org/10.1212/wnl.0000000000011226.

151. Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W. Biomarkers for tau patholgy. Mol Cell Neurosci. 2019. https://doi.org/10.1016/j.mcn.2018.12.001.

152. Fleisher AS, Pontecorvo MJ, Deveus MD, Sr M, Lu M, Arora AK, Truocchio SP, Wolters EE, Ossenkoppele R, Verfaillie SC, Coomans EM, Timmers T, Meyer PF, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S. doi. org/10.15252/emmm.202012921.

153. Tsai RM, Bejanin A, Lesman-Segev O, Lajoie R, Visani A, Bourakova V, Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, Ohlsson

154. Linberg A, Knight AC, Sohn D, Rakos L, Tong J, Radelet A, Mason NS, Stehouwer JS, Lopresti BJ, Klunk WE, et al. Radiosynthesis, In Vitro and In Vivo Evaluation of [(18)F]T89-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. ACS Chem Neurosci. 2021. https://doi.org/10.1021/acschemneuro.0c03080.

155. Venkatramani A, Panda D. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies. Int J Biol Macromol. 2019. https://doi.org/10.1016/j.biomac.2019.04.120.

156. Duggal P, Mehra S. Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia. Current Status of Clinical and Preclinical Findings. J Alzheimers Dis Rep. 2019. https://doi.org/10.1007/s13195-019-0470-7.

157. Tsai RM, Miller Z, Koestler M, Rojas JC, Ljubenkov PA, Rosen HJ, Rabinovic GD, Fagan AM, Cobigo Y, Brown JA, et al. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and CorticoBasal Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020. https://doi.org/10.1001/jamanet.2019.3812.

158. Fernandez-Valenzuela JL, Sanchez-Varela R, Muñoz-Castro C, De Castro V, Sanchez-Mejias E, Navaaro V, Jimenez S, Nuñez-Diaz C, Gomez-Abregoledas A, Moreno-Gonzalez L, et al. Enhancing microtubule stabilization rescues cognitive deficits and ameliorates pathological phenotype in an amyloidogenic Alzheimer’s disease model. Sci Rep. 2020. https://doi.org/10.1038/s41598-020-71767-4.

159. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01492374?term=BM5-24102#&rank=2. Accessed 26 Dec 2021.

160. Zhang B, Yao Y, Corneal AS, Oukoloff K, James MJ, Koivula P, Trojanowski JQ, Smith AB 3rd, Lee VM, Ballatore C, Brunden KR. A brain-penetrant triazolopyrimidinylamine enhances microtubule-stability; reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. Mol Neurodegener. 2018. https://doi.org/10.1186/s13247-019-0029-1.

161. Oukoloff K, Nzou G, Varricchio C, Lucero B, Alle T, Kovalevich J, Monti L, Corneal AS, Yao Y, James MJ, et al. Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazol[1,5-alapyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. J Med Chem. 2021. https://doi.org/10.1021/acs.jmedchem.0c01605.

162. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996. https://doi.org/10.1073/pnas.93.20.11213.

163. Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Koek KA, Wischik DJ, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2021. https://doi.org/10.1016/s0140-6736(16)31275-2.

164. Shells H, Schelter BQ, Bentham P, Babbedge TC, Rubino CM, Ganesan H, Hamburger J, Vukosavic V, Staff RT, Murray AD, et al. Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. J Alzheimers Dis. 2020. https://doi.org/10.3233/jad-191173.

165. Nieznanska H, Boyko S, Dec R, Redowicz MJ, Dzwolak W, Nieznanski K. Neutotoxicity of oligomers of phosphorylated Tau protein carrying tauopathy-associated mutation is inhibited by prion protein. Biochim Biophys Acta Mol Basis Dis. 2021. https://doi.org/10.1016/j.bbadis.2021.166209.

166. Soeda Y, Saito M, Maeda S, Ishida K, Nakamura A, Kojima S, Takashima A. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau comparison of the tau PET tracers [(18)F]flortaucipir and [(18)F]MK-6240 in human subjects. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.254961.
Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease. J Alzheimer's Dis. 2019. https://doi.org/10.3233/jad-181001.

178. Shin S, Kim D, Song JY, Jeong H, Hyeon SJ, Kowall NW, Ryu H, Pae AN, Lim S, Kim YK. Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy. Prog Neurobiol. 2020. https://doi.org/10.1016/j.pneurobiol.2020.101782.

179. Imbimbo BP, Ippati S, Watling M, Balducci C. A critical appraisal of tau-180. Di J, Siddiqui L, Lizz, Malik G, Hornung S, Dutta S, Hurst L, Issaya E, Wang A, Tu S, et al. The molecular tweezers CLP01 improves behavioral deficits and reduces tau pathology in P301T-tau transgenic mice. Alzheimers Res Ther. 2021. https://doi.org/10.1186/s11195-020-00743-x.

181. Liu M, Desheimer T, Sui D, Hovde S, Deng X, Kwok R, Bochar DA, Kuo MH. Hyper phosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer’s disease and cognitive functions. Sci Rep. 2020. https://doi.org/10.1038/s41598-020-07368-2.

182. Ahmed T, Van der Jeugd A, Caillierez R, Buée L, Blum D, D’Hooge R, Valencia A, Bieber VLR, Bajrami B, Marsh G, Hamann S, Wei R, Ling K, Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, VandeVrede L, Dale ML, Fields S, Frank M, Hare E, Heuer HW, Keith K, Wang X, Li W, Marcus J, Pearson M, Song L, Smith K, Terracina G, Lee Chakravarthy M, Chen S, Wang T, Veedu RN. Development of Novel AntiSense Oligonucleotide Therapeutics for Alzheimer’s Disease. J Alzheimers Dis. 2019. https://doi.org/10.3233/jad-190635.

183. Defensor E, Mok SA, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2020. https://doi.org/10.1038/s41551-021-00759-0.

184. Lewis J, Giasson BI, Davies P, Golde TE, Levites Y. Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons. Nat Commun. 2020. https://doi.org/10.1038/s41467-020-16984-1.

185. Feng Q, Luo Y, Zhang JN, Yang XF, Hong KY, Sun DS, Li XC, Hu Y, Li XG, Zhang JF; et al. MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration. Autophagy. 2020. https://doi.org/10.1080/15548627.2019.1638862.

186. Alzheimers Res Ther. 2021. https://doi.org/10.1186/s11195-020-00743-x.

187. Caroiu JM, Sargeant TJ. Rapamycin and Alzheimer disease: a double-edged sword? Autophagy. 2019. https://doi.org/10.1002/acr.20467. 2019.1615823.

188. Liu X, Hebron ML, Mulki S, Wang C, Lekah E, Ferrante D, Shi W, Kudrnova MB, Moussa C. Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer’s Disease. J Alzheimers Dis. 2019. https://doi.org/10.3233/jad-190635.

189. Liu X, Hebron ML, Mulki S, Wang C, Lekah E, Ferrante D, Shi W, Kudrnova MB, Moussa C. Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer’s Disease. J Alzheimers Dis. 2019. https://doi.org/10.3233/jad-190635.

190. Schmidt MF, Gan ZY, Komander D, Dewson G. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. Cell Death Differ. 2021. https://doi.org/10.1038/s41418-020-00706-7.

191. Hwang J, Nandola L, Zou, Rauch JN, Reis SA, Giroux M, Karch CM, Boctor D, Sibih YE, Storm NJ, Diaz A, et al. A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aat3005.

192. Ng PY, Chang IS, Koh RY, Chey SM. Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development. Metab Brain Dis. 2020. https://doi.org/10.1007/s11011-020-00591-6.

193. Joly-Amado A, Davtyan H, Serraneau K, Jules P, Zitnyar A, Pressman E, Zagorski A, Antontyan T, Hovakimyan A, Paek HJ, et al. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology. J Alzheimers Dis. 2020. https://doi.org/10.1016/j.jalz.2019.10.007.

194. Novak P, Kovacekova E, Zilka N, Novak M. Ten Years of Tau-Targeted Immunotherapy. The Path Walked and the Roads Ahead. Front Neurosci. 2018. https://doi.org/10.3389/fnins.2018.00798.

195. Theunis C, Crespo-Biel N, Gáñan V, Pihlgren M, López-Deber EM, Fisseha N, Budur K, et al. Prevention of tau seeding and clinical development. Metab Brain Dis. 2020. https://doi.org/10.1007/s11011-020-00591-6.

196. Albert M, Mairet-Coello G, Danis C, Lieger S, Caillierez R, Carrier S, Skrobala E, Landrieu I, Michel A, Schmitt M, et al. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Brain. 2019. https://doi.org/10.1093/brain/awz100.

197. Winston CN, Aulston B, Rockenstein EM, Adame A, Prikhodko O, Dave KN, Mishra P, Rissman RA, Yuan SH. Neuronal Exosome-Derived Human Tau is Toxic to Recipient Mouse Neurons in vivo. J Alzheimers Dis. 2019. https://doi.org/10.3233/jad-180776.

198. Goodwin MS, Sinyavskaya O, Burg F, O’Nell V, Ceballos-Diaz C, Cruz PE, Lewis J, Giasson BI, Davies P, Golde TE, Levites Y. Anti-tau scFv Targets to the Cytoplasm or Secretory Pathway-Variable Modify Pathology and Neurodegenerative Phenotypes. Mol Ther. 2021. https://doi.org/10.1016/j.ymthe.2020.10.007.

199. Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendebauonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021. https://doi.org/10.1016/s1474-4422(20)30489-4.

200. Jabbari E, Duff KE. Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nat Med. 2021. https://doi.org/10.1038/s41591-021-01465-9.
